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ABSTRACT OF THE DISSERTATION
Comprehensive characterization of the genetic and neoantigen landscapes of follicular
lymphoma patients supports the feasibility of personalized cancer vaccine treatments
by
Cody Alexander Ramirez
Doctor of Philosophy in Biology and Biomedical Sciences
Human & Statistical Genetics
Washington University in St. Louis, 2021
Professor Obi L. Griffith, Chair

Follicular lymphoma (FL) is the most common indolent non-Hodgkin’s lymphoma; however, it
remains incurable with conventional therapies and is poorly responsive to checkpoint blockade.
FL arises from B-lymphocytes and develops slowly (and often asymptomatically). A major
research focus has been on how to avoid chemotherapy treatments, to limit the potential
development of treatment-related side effects, and the risk of therapy-related second cancers. FL
also carries an approximately 30% lifetime risk of transforming from an iNHL to more
destructive lymphomas, which are associated with poorer prognosis. The most common
transformation results in diffuse large B-cell lymphoma (DLBCL). However, many patients may
not require treatment for decades and can be safely observed after their initial diagnosis.
Therefore, understanding the underlying genetic landscape and molecular mechanisms of FL
progression and identifying biomarkers of prognosis and novel drug targets is critically
important. Unfortunately, characterizing the genetic landscape of cancer remains a challenge
given cancer’s genetic diversity and clonal evolutionary properties. This complexity makes the
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job of understanding the mechanisms of cancer progression difficult to dissect. Unlike better
profiled cancers, FL is characterized by clinical and pathological features, but lacks a
comprehensively characterized genetic landscape. To address the need for a comprehensive
genetic landscape of FL; we developed a custom capture panel, sequenced over 500 samples
from over 370 patients, deconvoluted sample swaps, and conducted a genetic analysis as
described in Chapter 2. We found that FL has a low to medium mutation burden which is
consistent with current research. However, the question remained as to how many of these
somatic mutations could actually represent high quality neoantigens. It should be noted that only
a weak correlation exists between mutation burden and response to immune therapies while other
studies have shown relatively few immunogenic neoantigens are necessary for a detectable
response. Therefore, we hypothesized that immune based therapies, specifically personalized
neoantigen cancer vaccines, have the potential to cure patients and avoid some of the
consequences of conventional therapies. Personalized cancer vaccines aim to stimulate the
immune system to selectively increase T-cell populations that react to tumor specific neoantigens
to target and eliminate cancer cells. BioVaxID, a personalized idiotype cancer vaccine, showed
early promise as a new active immunotherapy to treat FL. However, BioVaxID contained only a
single cancer target and recently failed to meet their primary end points within a Phase III
clinical trial. We set out to determine (in Chapter 3) whether whole exome sequencing and RNA
sequencing could infer a patients’ MHC Class I alleles, and identify neoantigens and oligoclonal
B-cells, to engineer personalized cancer vaccines. Additionally, we initiated a pilot trial using
personalized neoantigen vaccine therapy combined with PD-1 blockade on patients with relapsed
or refractory follicular lymphoma (NCT03121677). Initial results described in Chapter 3
demonstrates feasibility, safety, and potential immunologic and clinical responses. These
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chapters describe next-generation sequencing analysis methods that can be utilized to determine
and streamline the feasibility of personalized cancer vaccines in FL and other cancers.
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Chapter 1: Introduction and Background
1.1 Introduction
Cancer is a catastrophic disease caused by genetic mutations that promotes unchecked cell
growth and proliferation in various tissues and organs of the body and is the second leading
cause of death in the United States. However, major improvements in detection and treatment
have been made, causing incidence rates to steadily decrease on average per year since 1999
(Henley et al., 2020). The greatest improvement in cancer detection followed the invention of
new DNA sequencing instruments and methods, collectively known as next generation
sequencing (NGS) technologies, which can process millions of read sequences in parallel in a
single instrument run compared to previous Sanger methods. These techniques have ushered in a
new era of genomic data production and with it a new era of genomic research.
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1.2 Overview of Next Generation Sequencing (NGS)
Within a short window of time immediately after the completion of the Human Reference
Genome, several different technologies and companies emerged with different technologies and
methods for next generation sequencing (Mardis, 2011, 2013, 2014). These new methods of
genomic detection significantly reduced the time, resources and costs to generate genome
sequencing data while simultaneously increasing the level of accuracy and precision of genomic
alterations identified, including expression patterns/signatures and other molecular features of
tumors and their microenvironments (Dellaire & Arceci, 2014). Some of the early commercial
contributors include, but are not limited to, Roche Life Sciences, Thermo Fisher Scientific,
Illumina, and Applied Biosystems. Currently, Illumina leads the next-generation sequencing
market providing a competitive cost, high quality of sequencing data, and allowing for a wide
range of applications (i.e., whole genome, whole exome, RNA sequencing, etc.) (Krishna et al.,
2019).

1.2.1 Generating NGS Data
Generating Illumina next-generation sequencing data involves three main steps: 1) Sample
preparation and library construction, 2) Cluster generation and 3) Sequencing (Bentley et al.,
2008). Three main tissue preparation techniques exist and can heavily influence the overall
quality of your sequencing data. The main factor is that the quality of the DNA extracted will
determine the end quality and ultimately the final results of your sequencing data. The
commonly used phrase “garbage in, garbage out” in computer science best summarizes why
starting with quality DNA is so important. Therefore, the best starting material is fresh material
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that has just been collected and then is immediately used for library construction. The fresher the
material the less time has been allowed for proteins to degrade, meaning that the quality of the
DNA being collected would be at its absolute peak. However, if you are unable to collect a fresh
sample then your next best option would be to use a fresh-frozen sample. Fresh-frozen samples
are collected and within the hour are flash frozen and stored in -80oC to be used later. The
overall quality of fresh-frozen samples is comparable to fresh samples. The last tissue
preparation technique is Formalin-Fixed Paraffin-Embedded (FFPE) and it is the least optimal to
use when conducting next-generation sequencing as it can suffer from cross-linking, heavy
DNA/RNA degradation, and fragmentation of DNA/RNA molecules which will directly affect
overall sequencing data quality (Cho et al., 2017; Esteve-Codina et al., 2017; Gallegos Ruiz et
al., 2007; X. H. Gao et al., 2020; Lehmann & Kreipe, 2001; Solassol et al., 2011; Suciu et al.,
2016). Lastly, before you can begin library construction you need to first isolate the nucleic acid
(DNA or RNA) of interest as starting material. Several hundred different nucleic acid extraction
kits exist and vary widely depending on your starting material (tissue, blood, cell, etc.).
However, they all follow the same basic logic: 1) breaking open the cell membrane, 2) breaking
down nucleic acid of interest, 3) separate nucleic acid from everything else and then 4) purify
nucleic acids. Several library preparation methods exist depending on the type of sequencing
data you want to collect from your sample, but all preparation methods typically add adapters to
the end of the DNA fragments. Through reduced cycle amplification additional motifs are
introduced, such as the sequencing binding site, indexes and regions complementary to the flow
cell oligos. Clustering involves hybridizing the resulting product (DNA fragments with adapters
ligated) onto a solid surface that contains a lawn of complementary oligo sequences and
enzymatically amplifying the fragments (Bentley et al., 2008). This step ensures that a sufficient
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number of fragments exist to properly emit a signal during the sequencing reaction for
instrument detection. Once cluster generation is complete, the reverse strands are cleaved and
washed away and the 3’ ends are blocked to prevent unwanted priming, thus only the forward
strands remain. Sequencing begins with the addition of the first sequencing primer to produce the
first read. With each cycle, fluorescently tagged nucleotides compete for addition to the growing
chain. Only one nucleotide is incorporated at a time based on the sequence of the template. After
the addition of each nucleotide, the clusters are excited by a light source and a characteristic
fluorescent signal is emitted (Bentley et al., 2008). This step is a point of potential sequencing
error as inefficiencies in sequencing chemistry, camera system malfunctions and the interference
of neighboring clusters or stray nucleotides can cause the addition or loss of a nucleotide call
within the sequence. The number of cycles determines the length of the read and the emission
wavelength with the signal intensity determines the base call. Because this process occurs on a
solid surface, hundreds of millions to billions of clusters can be sequenced in parallel at a single
time. Then after the forward strand read clusters are sequenced, they are washed away and the
remaining template is bound to the reverse oligo on the flow cell to begin sequencing of the
reverse strand. The average read length produced is relatively short (150-300bp) when compared
to the traditional Sanger sequencing read lengths (800bp).

1.2.2 Aligning NGS Data
Following the production of short read sequencing data, the single- or paired-end reads are
typically aligned to the human reference genome as the first step in downstream analysis (e.g.,
variant detection). However, using a reference genome for alignment comes with important
caveats. The human reference genome still contains major gaps of missing data and roughly 48%
4

of the human genome contains repetitive elements which complicates mapping of short reads.
Furthermore, the “reference” genome does not take into account the extreme amount of genetic
diversity that exists within the human species encompassing the entire world. The current human
reference genome (GRCh38) is a composite genome derived from several different anonymous
individuals. Therefore, differences between the genome you are studying, and the reference
genome may exist as natural variation (including single nucleotide polymorphisms,
chromosomal inversions, deletions and translocations) and affect alignment.

1.2.3 Variants identified and how somatic mutations contribute to tumor
formation
Following alignment, duplicate reads, which have the same start and end positions as aligned to
the reference genome, are typically removed and variants are called. Duplicate sequencing reads
can become a problem when low quality or degraded samples are used as input which can cause
PCR ‘jackpotting’. PCR ‘jackpotting’ is the result of preferential enzymatic amplification of
small DNA fragments by the polymerase. Skipping deduplication can result in false positive
variant calls in later steps. After deduplication, variant calling algorithms can be used to identify
germline and somatic mutations within the DNA sequence being studied when compared to the
reference genome or between tumor and matched normal genomes. Typically, any nucleotide
differences found when compared to the reference genome will be reported as a variant. Genetic
variations identified within a normal sample are referred to as germline mutations and presumed
to be inherited and affect the DNA of every cell in the individual’s body. Cancer causing
germline mutations play a major role in about 5 to 10 percent of all cancers, according to the
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National Cancer Institute. For example, individuals harboring a pathogenic germline variant
within BRCA1 or BRCA2 are characterized by a noticeably increased lifetime risk for breast and
ovarian cancers (Petrucelli et al., 1998). However, a majority of cancers are caused
predominantly by somatic mutations, which occur within non-germline cells and are not
inherited (Tomasetti et al., 2017). Somatic variants include single nucleotide variants (SNVs),
small insertions and deletions (Indels), structural variants (SVs), copy number alterations
(CNVs), and loss-of-heterozygosity (LOH) events (Stratton et al., 2009). Somatic mutations can
only be found in cell lineages or tissues derived from these initially mutated cells (Figure 1.1).

Figure 1.1: The acquisition and processes that contribute to somatic mutations over a cell's lifetime.
Figure originally published in (Stratton et al., 2009). “Mutations may be acquired while the cell lineage is
phenotypically normal, reflecting both the intrinsic mutations acquired during normal cell division and the
effects of exogenous mutagens. During the development of the cancer, other processes, for example DNA
repair defects, may contribute to the mutational burden. Passenger mutations do not have any effect on the
cancer cell, but driver mutations promote clonal expansion. Relapse after chemotherapy can be associated
with resistance mutations that often predate the initiation of treatment.”

According to the US National Cancer Institute’s Surveillance Epidemiology and End Results
(SEER) Database, more than half of all cancers materialize within individuals older than 66.
Aging is a major risk factor for cancer development due to the accumulation of somatic
6

mutations and cellular damage over time (López-Otín et al., 2013; Moskalev et al., 2013). Cells
replicate their DNA and divide billions of times. With each replication comes a small but nonzero risk of the introduction of mutational events or errors in the replication process (Figure 1.1).
Other causes of somatic mutations include, but are not limited to, errors introduced because of 1)
carcinogens, 2) errors in DNA damage repair, 3) epigenetic modifications and 4) indels resulting
from mobile genetic elements. The majority of somatic mutations that occur within our cells
during our lifetime are considered harmless, though a subset of these mutations occurs within a
gene or regulatory element, thus potentially leading to the formation of cancer (Figure 1.1).
These two types of somatic mutations can be organized into two groups: 1) “driver mutations”,
which confer a selective advantage for the cellular population inducing carcinogenesis and 2)
“passenger mutations”, which confer no selective advantages (Figure 1.1). “Driver mutations”
can be further categorized into two distinct groups of mutation causing events: 1) inactivation of
tumor suppressor genes and 2) activation of proto-oncogenes to create an oncogene. Tumor
suppressor genes maintain cellular replication, repair DNA damage, or control apoptosis. For
example, mutations or complete deletions of the tumor suppressor gene TP53 causes genomic
instability, inducing carcinogenesis (Hollstein et al., 1991). Proto-oncogenes are genes normally
expressed within cells that promote cellular growth. For example, a well-studied proto-oncogene
is KRAS, which is known to cause cancer upon receiving an activating mutation that aberrantly
promotes uncontrollable growth (Kranenburg, 2005). Additional somatic mutations can emerge
during a patient’s treatment that confer treatment resistance, sometimes leaving the patient with
limited to no treatment options (Figure 1.1). However, identifying and interrogating all somatic
mutations within any cancer increasingly allows the opportunity to implement sophisticated
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prevention techniques and create personalized treatment options that highlight the importance of
somatic mutations within cancers.
Somatic mutations are harder to identify than germline mutations because somatic variant
allele frequency (VAF) can vary drastically within a single tumor cell population unlike germline
variants which are present in all cells. Factors such as, but not limited to; 1) the overall presence
of the somatic mutations within the entire tumor cell population, 2) the purity of the tumor
sample taken from the patient, 3) sequencing depth and coverage of the variant in question, and
4) false positive variant calls can influence the VAF of a somatic mutation. VAF is one of many
important factors taken into account when identifying somatic variants through programmatic
algorithms and during manual review. However, each type of somatic mutation that exists
(SNVs, Indels, CNVs, SVs, fusions etc.) come with their own unique factors and complex
caveats that need to be taken into account when attempting to properly identify them. Therefore,
specifically designed variant callers exist for each somatic mutation type or subsets of variant
types (e.g., SNVs and Indels). Because several somatic variant callers exist for unique mutational
types and take into account different factors it has become common practice to use multiple
variant callers and use the union of the results to create an all-inclusive somatic result.
Algorithms that have been developed to identify these somatic mutations have been integrated
into automated pipelines to standardize variant calling procedures (Griffith et al., 2015; Xu,
2018). After variant calling has been completed, it is considered best practice to then manually
review every variant identified to ensure no false positives occurred. Manual review is a complex
and tedious task with multiple variables that need to be taken into account. In a recent
publication by (Barnell et al., 2019), we described in detail a step-by-step walkthrough of how to
conduct manual review of sequencing data with paired tumor and normal samples.
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1.2.4 Annotating NGS Data
Manually reviewed variants can be annotated to determine the resulting protein level effects and
predicted functional consequences caused by the somatic mutations identified. Some tools used
to annotate and predict functional impact include Variant Effect Predictor (VEP) (McLaren et al.,
2010, 2016), SIFT (P. Kumar et al., 2009; Ng & Henikoff, 2006), CHASM (Carter et al., 2009),
PolyPhen-2 (Adzhubei et al., 2010), MutationAssessor (Reva et al., 2011) and ParsSNP49 (R. D.
Kumar et al., 2016). Depending on the annotation tool you decide to use, somatic mutations can
be classified into a single or multiple consequence depending on their effect on the resulting
protein sequence. For example, VEP annotates somatic variants to at least one of the total thirtysix potential consequences that VEP has defined. Some somatic mutations have no effect at the
protein level. These DNA mutations are referred to as synonymous mutations. Other somatic
mutations might change the expression profile of the gene, alter the protein structure and even
modify a phenotype of the organism just to list a few. Mutations that change the amino acid, and
usually the protein, are referred to as nonsynonymous mutations. A few common and important
nonsynonymous mutation types include: 1) missense variants, in which a single amino acid is
altered to another amino acid, 2) stop gained, in which a single amino acid change results in a
premature stop codon leading to a shortened transcript and 3) frameshift variant, in which either
the addition or subtraction of amino acids causes a disruption of the translational reading frame
and potentially introduces a premature stop codon. Variant annotation is extremely important and
informative clinically as it can be used to identify diagnostic, prognostic and
predictive/therapeutic biomarkers associated with drug mechanisms (Ainscough et al., 2016;
Cerami et al., 2012; Chakravarty et al., 2017; Futreal et al., 2004; J. Gao et al., 2013; Griffith et
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al., 2017; Huang et al., 2017; Tamborero et al., 2001; Van Allen et al., 2014). The quick
identification of therapeutically relevant variants due to the speed and accuracy of nextgeneration sequencing and automated programmatic analysis pipelines lead to the formation of
precision oncology and laid the groundwork for the emergence of personalized cancer vaccines.
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1.3 Overview of follicular lymphoma (FL)
FL is the second most common Non-Hodgkin’s lymphoma (NHL) and the most common
indolent NHL (Jemal et al., 2011). While FL is often initially responsive to standard therapies, it
remains incurable, leaving relapsed/refractory FL patients with little to no effective treatment
options (Kahl & Yang, 2016). FL also carries an approximately 30% lifetime risk of
transforming from an iNHL to more destructive lymphomas, which are associated with poorer
prognosis (Carlotti et al., 2009; Casulo et al., 2015; Correia et al., 2015). The most common
transformation results in diffuse large B-cell lymphoma (DLBCL). However, many patients may
not require treatment for years or decades and can be safely observed after their initial diagnosis
(Jacobson & Freedman, 2015). Therefore, understanding the underlying genetic landscape and
molecular mechanisms of FL progression and identifying biomarkers of prognosis and novel
drug targets is critically important.

1.3.1 The promise of precision medicine in FL
The field of precision medicine aims to provide individual treatment based upon each patient’s
individual genomic profile and relevant factors (Garraway et al., 2013). Previous studies have
demonstrated that molecular characteristics detected by genome sequencing may change the
diagnostic, prognostic, and treatment decisions made by a clinician (Barnell et al., 2021). This
approach has the potential to yield positive results, less toxicity, and improved quality of life by
being able to improve risk stratification of patients receiving first-line immunochemotherapy
(Pastore et al., 2015) or discovering novel treatment options for patients with multiple relapses
(Griffith et al., 2016). However, a better understanding of the genomic landscape is needed if the
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promise of precision medicine is to be realized for FL patients. The identification of biomarkers
and significantly recurrent mutations in cancers through genomic analysis remains one of the key
challenges in the field of precision oncology (Van Allen et al., 2013). Detection of SNVs and
Indels through the use of statistical automation has improved drastically. However, automated
detection of complex SVs, CNVs and RNA fusions still frequently fail to differentiate true
events from sequencing or mapping artifacts, leading to poor precision and recall (Carrara et al.,
2013; Lin et al., 2011; Talwalkar et al., 2014). The t(14;15) translocation event is a FL hallmark
and thus, accurate detection of this event and other possible fusions is of great importance in the
interpretation of FL (Kridel et al., 2012).

1.3.2 Gaps in the genomic landscape of FL
FL has long been known to have cell-essential genetic mutations (e.g. the hallmark t(14;15)
translocation results in BCL2 overexpression) and suffer from FL microenvironment changes
(Basso & Dalla-Favera, 2015; Nowakowski & Ansell, 2014; Scott & Gascoyne, 2014). The FL
microenvironment is composed of numerous amounts of immune cells, stromal cells, blood
vessels and extracellular matrix. However, the diversity and organization of the resulting FL
microenvironment depends on the tumors genetic landscape of somatic mutations, how
dependent the tumor is on outside stimuli for survival and overall immune activity. Early on the
tumor cells are still dependent on cells within its microenvironment for survival and growth
signals, while diversity and spatial organization of the FL microenvironment is similar to that of
normal lymphoid tissue. All of these factors will result in the “re-education” pattern (Figure
1.2).

12

Figure 0.2: Common composition and organization of B-cell lymphoma microenvironments.
This figure was originally published in (Scott & Gascoyne, 2014). “The figure depicts the typical
microenvironment of the three B cell lymphoma subtypes that represent the extremes of the spectrum of
tumour microenvironment — 'recruitment', 're-education' and 'effacement'. These lymphoma subtypes
represent the range of tumour cell content, ranging from ∼1% in Hodgkin's lymphoma to typically more
than 90% in Burkitt's lymphoma (BL). The other B cell lymphomas fall within this range, as shown for
the most common B cell lymphomas (centre). Typically, the ratio of malignant cells to
microenvironmental cells increases across the range, from classical Hodgkin's lymphoma to BL, as
shown. DLBCL, diffuse large B cell lymphoma; FOXP3, forkhead box protein P3; HRS, Hodgkin Reed–
Sternberg; MALT, mucosa-associated lymphoid tissue; MCL, mantle cell lymphoma; TFH, follicular T
helper; TH, T helper; TFR, follicular regulatory T.”
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Recent publications have discovered and validated several genetic mutations that occur in FL
through the use of next-generation sequencing, especially those associated with transformation
(Correia et al., 2015; Green et al., 2013; Okosun et al., 2014; Pasqualucci et al., 2014; Pastore et
al., 2015). These strategies have led to both an increased understanding of the FL genetic
landscape and demonstrated that there is still much to learn. For example, recently, recurrent
somatic alterations were discovered involving EZH2 (Morin et al., 2010) and KMT2D/MLL2
(Morin et al., 2011), despite the small sample set of the studies. The research that discovered
EZH2 as recurrently mutated used a single FL patient to guide the identification of interesting
mutations and then proceeded to only sequence EZH2 in about 500 more samples. This gave
them an unparalleled ability to state the recurrence of EZH2 mutations within NHL, as they only
focused on a single gene of interest (Morin et al., 2010). A year later, Morin et al. was then able
to discover the recurrence of KMT2D/MLL2 by conducting comprehensive exploratory
sequencing on 13 DLBCL patients and RNA sequencing on 113 NHL samples. Unfortunately,
only 12 out of the total 126 samples sequenced for discovery were FL patient samples. Only a
small set of 8 significantly mutated genes were used to move forward with validation in other
samples (Morin et al., 2011). These two previous publications had limited ability to
comprehensively characterize FL, as they focused on only a handful of genes, thus narrowing
their window of discovery. Several studies have conducted exome sequencing on a small
discovery cohort of FL patients and then proceeded to validate highly recurrent mutations
discovered by running extension sequencing in larger patient cohorts (Green et al., 2015; Krysiak
et al., 2017; Li et al., 2014; Morin et al., 2011; Okosun et al., 2016; Yildiz et al., 2015). Through
the utilization of a small custom capture panel (74 genes) on the largest patient cohort to date, a
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study was able to identify seven recurrently mutated genes resulting in the clinicogenetic risk
model termed m7-FLIPI (Pastore et al., 2015). These studies have further revealed significantly
important mutations and associations in regard to the pathobiology of FL through the use of
small cohorts and focused gene panels. However, an incomplete picture of FL patient tumors
remains as long as we do not comprehensively identify all mutations within a patient’s tumor
using whole genome sequencing. Studies to date have included either a very small sample size
for whole genome sequencing approaches or very small gene panels when larger sample
numbers were available. Therefore, this potentially leaves actionable, predictive and prognostic
variants unidentified. Such correlations will ultimately influence patient treatments by allowing
us to predict patient outcome, therapy resistance mutations, new drug targets and much more.
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1.4 Emergence of cancer immunotherapies with FL
1.4.1 Foundational research
The emergence of modern immunogenomics began during the late 1980s when scientists started
researching cancer immunology. Their research focus depended on several main theories
concerning cancer biology, the human immune system mechanism of action and how/if they
interacted with each other. They theorized that cancer cells expressed novel tumor-specific
peptides (a result of their unique genomic alterations) that could be displayed on their cell
surface by MHC Class I molecules. The presentation of a novel peptide by the MHC Class I
molecule could then be recognized by CD8+ cytotoxic T-cells and cause T-cell activation,
eventually leading to lysis of the cancer cell. The above theory was supported by previous work
conducted in non-viral cancers by Old (Old & Boyse, 1964), Gross (Gross, L. Cancer Res. 3(5):
326–333 (1943)), Foley (Foley, 1953), and Prehn (Prehn & Main, 1957). Methods to grow
antigen-specific cytolytic T lymphocytes in culture were later developed by (Cerottini et al.,
1974) and (Gillis & Smith, 1977) which would enable future researchers to validate neoantigens
of interest. Then to better understand antigen presentation, foundational research was conducted
to identify and comprehensively characterize MHC molecules by (Babbitt et al., 1985) and
(Bjorkman et al., 1987). Then, a year later the first missense mutation neoantigen was
successfully identified by (De Plaen et al., 1988). The work conducted thus far was not enough
to convince the research community that the human immune system was purposefully identifying
and attempting to eliminate patient tumors due to neoantigens. Therefore, van der Bruggen et al
moved forward and within 3 years successfully published a paper showing that they were able to
clone the first human neoantigen (van der Bruggen et al., 1991). Finally, several groups
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conducting research in human melanomas were able to successfully show that T-cells favorably
bound to cancer cells compared to normal cells from the same patients (Dubey et al., 1997;
Knuth et al., 1984; Robbins et al., 1996; Van den Eynde et al., 1989). Nearly half a century's
worth of research and knowledge had to be completed to give birth to cancer immunotherapy
research.

1.4.2 Cancer immunotherapies in FL
Cancer immunotherapy is any approach that attempts to utilize or activate a person’s immune
system to treat their cancer. These approaches take advantage of specific cell surface markers
that allow the patient’s immune system to target and destroy distinct cell types. Two main
categories of immunotherapies exist; 1) active immunotherapies attempt to influence and
empower a patient’s immune system to kill cancer cells and 2) passive immunotherapies are
created outside of the body to destroy cancer cells through the inclusion of manufactured
monoclonal antibodies, lymphocytes and cytokines. Rituximab was the first anti-CD20+
monoclonal antibody developed for the treatment of Non-Hodgkin’s Lymphoma of B-cell origin.
Rituximab was shown to improve overall survival for patients in randomized clinical trials and is
now a part of standard chemotherapy induction (Bachy et al., 2013; Federico et al., 2013; Herold
et al., 2003; Hiddemann et al., 2005; Marcus et al., 2008). Unfortunately, Rituximab suffers from
several adverse events, in the worst cases leading to disability and even death. The main reason
patients suffer from such serious adverse effects is because Rituximab targets CD20+ cells that
are widely expressed on all types of B-cells, both normal and cancerous, resulting in severe B
cell depletion. Specificity is thus a major limiting factor for the use of Rituximab as a treatment
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option within patients. As a result, there is a need for alternative targeted immunotherapies which
target cancerous cells while abstaining from harming normal cells.
A personalized cancer vaccine is a vaccine created from a patient’s somatic mutational
profile that can be used to treat an existing cancer. Optimally, normal/tumor DNA and tumor
RNA samples are sequenced from a patient. The resulting genetic data are then used to identify
cancer-specific mutations that are expressed. The resulting mutations are then used to identify
peptides that would cause a patient specific cytotoxic T-cell response. Validation can be
achieved using the patient peripheral blood mononuclear cells. Once immune-activating peptides
have been identified, they are injected into the patient along with an adjuvant to activate the
patient’s immune system to attack and kill their cancer. A benefit of personalized cancer
vaccines compared to anti-CD20+ monoclonal antibodies is that they can be highly specific and
decrease the risk of autoimmunity side effects. An additional benefit is that multiple targets can
be pursued in an attempt to eliminate all driver mutations and dominant tumor clones. Published
research data on early proof-of-principle use of human neoepitope vaccines originating from
single amino acid substitutions for which T cell reactivity has been experimentally validated can
be found as early as 2013 (Robbins et al., 2013). The majority of publications identifying and
validating neoepitopes has occurred within melanoma (Bassani-Sternberg et al., 2016; Carreno et
al., 2015; Cohen et al., 2015; Gros et al., 2016; Kalaora et al., 2016; Kelderman et al., 2016;
Linnemann et al., 2015; Lu et al., 2014; McGranahan et al., 2016; Ott et al., 2017; Pasetto et al.,
2016; Prickett et al., 2016; Pritchard et al., 2015; Robbins et al., 2013; Ugur Sahin et al., 2017;
Snyder et al., 2014; Strønen et al., 2016; van Rooij et al., 2013; Verdegaal et al., 2016). Patients
with this form of cancer are typically hypermutated, meaning that there was a high probability
that neoepitope candidates could be discovered. Several more papers have since been published
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in the pursuit of identifying neoepitope candidates for other tumor types (Anagnostou et al.,
2017; Bentzen et al., 2016; George et al., 2017; Khodadoust et al., 2017; Koşaloğlu et al., 2016;
Le et al., 2017; Lee et al., 2014; Mennonna et al., 2017; Nielsen et al., 2016; Parkhurst et al.,
2017; Rajasagi et al., 2014; Rizvi et al., 2015; Tran et al., 2014, 2015; Wick et al., 2014) in
response to the promising results observed within melanoma. Only 3 papers have been
published on identifying and validating neoepitopes within blood cancers (Khodadoust et al.,
2017; Lee et al., 2014; Nielsen et al., 2016), of which 2 focused on FL (Lee et al., 2014; Nielsen
et al., 2016) and only 1 made their data available (Nielsen et al., 2016). These studies serve as an
early proof-of-principle that neoantigen candidates can be identified within FL patients.

1.4.3 Identification of neoantigens before NGS
Many techniques were developed to identify neoantigens specifically for cancer immunotherapy
research (Caron et al., 2007; Khan et al., 2013). Unfortunately, only previously discovered
neoantigens could be identified through the use of various polymerase chain reaction (PCR)
techniques, as you needed to know the specific genomic locations, for a range of solid and blood
cancers. Additionally, some advanced PCR techniques relied on being able to detect the
difference of RNA expression between a normal sample and a tumor sample (Martelange et al.,
2000). (U. Sahin et al., 1995) developed a method of Serological analysis of tumor antigens by
Recombinant cDNA Expression cloning (SEREX) which was not limited to solely immunogenic
cancers, such as melanomas. SEREX is a tedious method but allows for a high-volume screening
of several neoantigens at a time. The process begins by extracting mRNA and reverse
transcribing them to create cDNA libraries from your sample of interest (such as tumor samples,
cell lines or normal samples). Then the cDNA is inserted into phage vectors and expressed as
19

recombinant proteins on the capsid surface of phages that survive. Then these remaining phages
are screened with diluted serum of the same patient. Neoantigens are then identified by their
reactivity with IgG antibodies present in the patient’s serum. Then any positive plagues are
isolated, eluted and used for secondary confirmation screening before they are finally sequenced
for identification. The biggest limiting factors when using the SEREX approach is time even
though several antigens can be screened at once. However, this approach was widely used and
led to the identification of over 2,000 neoantigens across multiple types of cancers. (Klade et al.,
2001) developed a method of Serological proteome analysis (SERPA). The process begins by
extracting proteins from your sample of interest through separation on 2DE gels and then
identified using mass spectrometry. Unlike the previous method, this approach allows for the
user to also identify neoantigens for specific post-translational modifications. The last commonly
used approach to identify neoantigens is cDNA microarrays. cDNA microarrays have been used
to identify the differential expression of neoantigens when comparing to normal and cancer
tissues. Several major issues exist with the above methods for identifying neoantigens which
would not allow the process to realistically be useful clinically. Therefore, a method that is both
encompassing of the entire human genome, accurate to the nucleotide level, does not require
previous knowledge of potential neoantigen locations, and is fast, was required.

1.4.4 Identification of neoantigens post-NGS
Two of the most time-consuming tasks included proper identification of somatic mutations and
determining a patient’s HLA types. However, the completion of the first human reference
genome in 2004, the invention of next-generation sequencing technologies, and the production of
automated next-generation sequencing analysis pipelines ushered in a new era for the
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identification of neoantigens which would make them clinically relevant. The first report of a
cancer genome being sequenced was published just 15 years ago in 2006 by (Sjöblom et al.,
2006). They analyzed over 13,000 genes in multiple breast and colorectal cancer samples and
showed that they contained an exceptional number of somatic mutations. Additionally, the
majority of mutations identified could theoretically become neoantigen relevant targets as 83%
of all mutations identified were determined to be missense mutations. Therefore, they conducted
an in-silico analysis of all the mutations identified by (Sjöblom et al., 2006) to identify candidate
neoantigens. They were able to find evidence that supported their theory that the tumorigenic
process results in the generation of multiple neoantigen targets. Just a few months later (Ley et
al., 2008) was able to sequence the first whole cancer genome, showing that whole-genome
sequencing was reasonably affordable and could be conducted within a reasonable time. Being
able to identify somatic mutations within cancers, showing that these somatic mutations could
then lead to neoantigens and that whole-genome sequencing could be conducted in an affordable
and timely manner meant that cancer vaccines could now be clinically relevant to the masses.
However, the potentially relevant neoantigens had not yet been validated in any way until two
independent groups showed just that in 2012. They were able to show that neoantigens could be
predicted from next-generation sequencing data that were immunologically reactive in murine
sarcoma models (Castle et al., 2012; Matsushita et al., 2012). These researchers were able to
finally answer whether or not neoantigens could be used in the fight against cancer, thus ushering
in the era of personalized cancer vaccines as a realistic treatment option for patients (Liu &
Mardis, 2017).
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MHC Class I allele alignment algorithms
There are a few processes that need to occur for a somatic mutation to cause an immune reaction
within a patient so that the cancer cells are eliminated. One of the most important steps when
attempting to identify and predict the immunologic reactivity of a neoantigen is the correct
identification of a patient’s human leukocyte antigen (HLA) types. That is because T-cell
activation is directly dependent on whether or not a neoantigen is being presented on the surface
of an antigen presenting cell which is facilitated by HLA protein complexes. The gold standard
method for determining a patient’s HLA haplotypes is PCR amplification (Bunce & Passey,
2013) due to the repetitive and highly polymorphic nature. However, conducting gold standard
HLA haplotyping can be laborious and expensive, so an alternative that is becoming more
common is computational HLA typing using a patient’s whole-genome, whole-exome, and/or
RNA sequencing data. Some HLA class I prediction algorithms have a 99% prediction accuracy
for four-digit resolution when compared to gold standard typing results (Bauer et al., 2018;
Kiyotani et al., 2017). These tools use one of two methods currently, either an alignment-based
approach or an assembly-based approach. For example, alignment-based HLA typing algorithms
such as PolySolver (Shukla et al., 2015) and OptiType (Szolek et al., 2014) (Figure 1.3) align
reads to the HLA reference genome and then use probabilistic modeling to predict HLA types.
While assembly-based algorithms such as ATHLATES and HLAminer conduct de novo contig
assembly which are then used to predict HLA types.
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Figure 1.3 HLA haplotype prediction based off of next-generation sequencing data.
Figure originally published in (Szolek et al., 2014). “OptiType’s four-digit HLA typing pipeline.
Reference libraries for genomics and CDS are generated by extracting exons 2 and 3 from each known
HLA-I allele. For genomic sequences, flanking intronic regions are also extracted. If some of these
regions are missing, phylogenetic information is used to reconstruct the missing segments from the
closest relative HLA-I allele. NGS reads are mapped against the so-constructed HLA allele reference (A).
From the mapping result a binary hit matrix CR×A is constructed for all reads r ∈ R mapping to at least
one allele a ∈ A of the reference with Cr,a = 1 if read r could be mapped to allele a; otherwise, Cr,a = 0
(B). Based on this hit matrix, an ILP is formulated that optimizes the number of explainable reads by
selecting up to two alleles (columns of the hit matrix) for each HLA-I locus (C). The selected alleles
represent the most probable genotype”

MHC Class I allele peptide binding prediction algorithms
Neoantigen identification and prioritization analysis pipelines have been established recently to
predict the binding affinity of neoantigens to the patient’s specific MHC Class I molecules
(based on HLA typing) because experimentally screening large numbers of neoantigen
candidates is an extremely expensive and time-consuming process. Therefore, computational
method development and the refinement of reference data sets used to predict neoantigen-MHC
molecule binding affinity remains an active area of research. The first few algorithms focused on
using in vitro peptide-MHC complex binding affinity measurement datasets as training data so
that they could predict results for novel peptide-MHC combinations. These machine learning
based approaches were able to take into account different and complex types of binding
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interaction sites and determine potential novel patterns of binding. A few of the machine learning
based methods utilized artificial neural networks and stabilized matrix methods. Recently
published methods have favored in vivo immunoprecipitation of peptide MHC complexes
preceded by mass spectrometry analysis or a combination of mass spectrometry and binding
affinity data (Bulik-Sullivan et al., 2018; Jurtz et al., 2017; O’Donnell et al., 2018). By using in
vivo datasets these algorithms had the opportunity to take into account unique features of
peptides that were actively processed and expressed on the cell surface. However, even though
the amount of information gained by the algorithms taking advantage of in vivo datasets is
important the total dataset used is small compared to the datasets used by other algorithms due
the laborious work to generate in vivo data. A recent publication showed that inclusion of
peptide elution data from mass spectrometry experiments improved the overall prediction
accuracy when studying naturally presented peptides (Zhao & Sher, 2018). An extensive list of
MHC Class I binding algorithms exists (Figure 1.4) and should be taken into account when
determining the inclusion of a neoantigen candidate into a patient’s vaccine.
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Figure 1.4 MHC Class I binding algorithms comparison.
Figure originally published in (Richters et al., 2019).

Neoantigen prioritization and vaccine design pipelines
Currently, predicting and designing a single personalized multiplexed cancer vaccine requires
numerous steps and analysis of large amounts of complex data which then needs to be filtered,
ranked and interpreted. The process can be summarized into five major steps: 1) Tumor and
matched normal sample acquisition and sequencing (whole-genome, whole-exome, and/or whole
transcriptome), 2) somatic variant identification (SNVs, Indels, SVs, etc.), 3) patient-specific
HLA haplotyping, 4) neoantigen candidate prediction and prioritization, 5) candidate selection.
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To help streamline and standardize the neoantigen prioritization process numerous bioinformatic
pipelines have been developed (Bais et al., 2017; Bjerregaard et al., 2017; Chang et al., 2017;
Hundal et al., 2020; Paul et al., 2016; Rubinsteyn et al., 2018; Schenck et al., 2019; Schubert et
al., 2015; Tappeiner et al., 2017; Wang et al., 2019; Wood et al., 2020; Z. Zhou et al., 2017).
These pipelines take into account multiple important factors that can heavily influence the
effectiveness of the neoantigen candidates. These factors include: 1) Using multiple binding
prediction algorithms, 2) Integrating both DNA and RNA data, 3) Phasing proximal variants, 4)
Interpreting variant clonality, 5) Evaluating HLA expression and 6) Predicting tumor
immunogenicity. Additionally, they summarize these factors and other potentially important data
to allow the user the ability to systematically review all candidates. However, most pipelines
currently only take into account SNVs and Indels, with a smaller subset considering gene
fusions. This is problematic as any tumor specific variants (SNVs, Indels, Fusions, SVs, Splicevariants resulting in a new protein, etc.) can lead to immunogenic neoantigens and we are
currently only able to analyze and select a handful of them. Additionally, cancers with unique
cell markers could also be used as potential neoantigen candidates but no current pipelines exist
to accommodate such targets. For example, follicular lymphoma arises in B-cell lymphocytes
which express extremely unique cell surface protein markers known as B-cell receptors which
could be used as neoantigen targets. Therefore, areas of improvement still exist for current and
future analysis pipelines to address when considering neoantigen identification and prioritization.

Cancer vaccine therapy delivery systems
Personalized cancer vaccines can be designed once neoantigen candidates have been selected.
However, multiple delivery mechanisms exist for use in patients; these include 1) Synthetic
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peptides, 2) DNA, 3) mRNA, and 4) ex-vivo-loaded dendritic cell vaccines currently (Guo et al.,
2018; Ugur Sahin & Türeci, 2018).
a) Synthetic long peptide vaccines: These vaccines are a mix of synthetic neoantigenic
peptides with adjuvant solutions which are then directly injected intramuscularly. The
peptides are a result of using the short epitope that was selected and flanking it with
additional amino acids that are adjacent to the sequence until a total of 15-30 amino acids
are selected. One downside of choosing to use synthetic long peptides is
manufacturability. Certain biophysical properties of amino acids can make peptide
synthesis difficult and long peptides will suffer from insolubility problems. Additionally,
they don't always solubilize well with one another so typically several cocktails must be
made in the adjuvant and administered separately. Furthermore, they are expensive to
manufacture because they have to be synthesized under good manufacturing practices
(GMP) conditions. Recently publications have found this delivery mechanism effective
within their immunotherapy preclinical studies and clinical trials (Keskin et al., 2019;
Kreiter et al., 2015; Ott et al., 2017; T. Schumacher et al., 2014).
b) DNA vaccines: These vaccines involve creating a circularized DNA insert carrying one
of more of the neoantigen sequences and inserting the result into a DNA vector. One
major downside to DNA vaccines is the sheer complexity of determining the order of
neoantigens sequences along with spacer sequences to ensure that no new strong binding
junctional epitopes are formed by the resulting complete vector sequence. This process
can be extremely time consuming and the number of factors that must be taken into
account can increase exponentially based on the number of neoantigen sequences
included. On the other hand, DNA vaccines are relatively inexpensive to produce, even
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for GMP-grade constructs. DNA vaccines are actively being used in research and clinical
trials (Aurisicchio et al., 2018; Duperret et al., 2019).
c) mRNA vaccines: These vaccines are similar to DNA and peptide vaccines however they
make use of synthetic RNAs to encode the neoantigens. One major downside is that RNA
vaccines suffer from major molecular stability problems and problems associated with
processing and presentation by antigen presenting cells. On the other hand, mRNA
vaccines can be directly injected and benefit from being readily translated once in the
cell, thus causing T-cell activation. mRNA vaccines were successfully utilized to treat 13
patients with advanced cutaneous melanoma (Ugur Sahin et al., 2017).
d) Ex-vivo-loaded dendritic cell vaccines: These vaccines are more tedious and complex to
make. First blood is collected from the patient. From that blood dendritic cells are
isolated and matured ex vivo in the presence of the neoantigen peptides selected. Once
the dendritic cells have fully matured, they are isolated and infused back into the patient.
Dendritic cell vaccination was recently used to treat 3 melanoma patients and caused Tcell activation in all patients (Carreno et al., 2015).

1.5 Determining the FL genomic and neoantigen landscape
The advent of NGS technologies now allows for the rapid and comprehensive identification of
molecular drivers and passengers of cancer. Increasingly, the knowledge provided by NGS data
through comprehensive genomic profiles supports the personalized treatment of cancer patients.
FL is a relatively indolent disease, but patients still suffer from treatment related side effects and
those with relapsed or refractory disease have poor outcomes. Initial surveys of the FL
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mutational landscape have been completed but major knowledge gaps remain in order to advance
personalized oncology for FL. One potentially promising new treatment approach is the
application of patient specific neoantigen cancer vaccines. However, the feasibility of this
approach has not yet been proven. In Chapter 2 we describe the steps required to successfully
collect and process clinical data from a large multi-institutional cohort study. These steps were
important because they directly influenced the number of patients, we later used during our
clinical data analysis when identifying correlations between clinical data and genetic mutations.
We conducted a meta-analysis of previous research to help determine which genes should be
added to a custom capture panel to increase coverage of the human genome while still
maintaining affordability. We were able to obtain a large number of tumor-only samples and
therefore had to implement a very thorough filtering strategy to reduce the number of false
positives. Considering the fact that sometimes cancer patients will travel across countries or even
the world, this could potentially lead to patients participating and providing samples to multiple
institutes. So, we theorized that since the cohort of patients included multiple institutes and all
clinical data collected was already de-identified that there could be a possibility that multiple
unique samples could actually be from a single patient. So, we conducted genetic pairwise
correlation analysis to determine if our cohort contained any samples that are genetically
identical and resolved them. Then we summarized the genetic landscape of the cohort and our
current genetic findings. In chapter 3 we present our work on determining whether whole exome
sequencing and RNA sequencing (RNA-Seq) could infer a patients’ MHC Class I alleles,
identify neoantigens and oligoclonal B-cells, to engineer personalized cancer vaccines.
Normal/tumor DNA and tumor RNA from 58 patients’ FL biopsies underwent WES and RNASeq. Potential somatic and B-cell clonotype neoantigens were predicted and filtered to identify
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high quality neoantigens. B-cell clonality was determined by alignment of BCR CDR3 regions
from RNA sequence data, grouping at protein level, and comparison to BCR repertoire of
healthy individuals. We then filtered down our list of predicted neoantigens to a final list of
neoantigen vaccine candidates. From these initial results we were able to obtain approval for a
clinical trial and we will briefly summarize our initial results from this on-going pilot trial.
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Chapter 2: Comprehensively describing the
genetic landscape of FL

Ramirez CA*, Krysiak K*, et al. Recurrent somatic mutations affecting chromatin modifying
pathway genes in follicular lymphoma. Targeted journal: Blood. 2021 March.
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2.1 Introduction
Our laboratory recently conducted research to further investigate the genetic landscape of FL and
subsequently published all findings in Blood (Krysiak et al., 2017). Initially, whole exome
sequencing was conducted on tumor/normal pairs from a discovery cohort of 24 patients with
FL. Manually reviewed and validated mutational variants discovered in this cohort were then
combined with mutations previously identified in other B-cell malignancies to create a custom
capture panel of 1,716 genes (Kiel et al., 2012; Lohr et al., 2012; Morin et al., 2010, 2011;
Pasqualucci et al., 2011; Puente et al., 2011; Quesada et al., 2011; Rossi et al., 2012; Schmitz et
al., 2012; Treon et al., 2012). This custom capture panel was then used to sequence 113 FL
tumor samples from 105 primarily treatment-naïve individuals. A total of 39 genes were found to
be significantly mutated when compared to background mutation rates. Mutations in CREBBP
were found to be associated with inferior progression-free survival, while mutations in HVCN1
were associated with improved progression-free survival. More importantly, this study found that
FL has more recurring mutations in the BCR signaling pathway, SWI/SNF complex and histone
genes than previously reported in the literature. Our laboratory identified novel recurrent
mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) and increased the number of genes
known to be mutated in FL. Additionally, de novo recurring mutations in BTK, SYK, and
HVCN1 were identified that may possess therapeutic and prognostic associations for FL. These
findings highlight the fact that our understanding and knowledge of mutations linked to FL
remains incomplete. Furthermore, the findings of direct clinical interest require larger cohorts to
validate their associations.
The purpose of this research chapter is to test whether next-generation sequence data can
be utilized to comprehensively genomically profile FL in an effort to bring precision medicine to
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FL patients through personalized treatment plan designs and personalized cancer vaccines.
Currently, FL lacks a comprehensively characterized genetic landscape. Additionally, there have
been no significant advances in FL treatment since the widespread adoption of Rituximab nearly
two decades ago. While our understanding of FL biology has improved, FL is still considered
incurable with standard chemotherapy (including Rituximab). Previously the field had been
limited by the prohibitive cost of sequencing and interpretation in the context of a rapidly
changing field of cancer genomics. Existing attempts to genomically profile FL are incomplete at
best. Studies have included either a very small sample size for whole genome sequencing
approaches or very small gene panels when larger sample numbers were available. This research
chapter will better define the complexity and heterogeneous nature of FL to improve our
understanding of how the disease may function.
We have previously shown that our knowledge and understanding of the genetic
landscape of FL remains incomplete by identifying previously unreported recurrent mutations.
Some of these mutations may confer therapeutic or prognostic associations for FL that could
potentially guide clinical decisions. However, in order to comprehensively describe the genetic
landscape of FL, a larger patient cohort is required to obtain sufficient statistical power as well as
increase the scope of genes interrogated. This chapter will better determine if novel significantly
mutated genes and mutational hotspots in FL have yet to be discovered. We hypothesize that
novel recurrently mutated genes will be identified in putative lymphoma-associated cellular
pathways as well as previously unrecognized pathways.
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2.2 Results
Design of an all-inclusive FL custom capture panel includes up to 13% of all coding genes.
We conducted a meta-analysis of previously published data to aid in the design of a custom capture
panel, expanding the gene pool to include previously unreported genes or pathways of interest.
Previously, 898 mutated genes were selected to be used in a custom capture panel (WUSM-LPv1)
from variants identified in a discovery cohort. In our revised design, we only included genes from
our previous study found to be recurrently mutated (>1) in samples when compared to 14
sequencing studies of other non-Hodgkins lymphomas (818 total genes). This allowed us to focus
our custom capture by eliminating genes that were originally included because they were found in
the discovery patient cohort, but never seen again. Additionally, we selected all genes recurrently
mutated (>1) in samples from the same 14 published sequencing studies to expand our custom
capture panel (897 total genes) as well as genes in the BCR and CXCR4 signaling pathways,
SWI/SNF complex and select histone genes (84 genes total). All genes were then ranked by
mutational load and disease to ensure significantly mutated genes were included along with genes
of clinical relevance. Approximately 2,697 genes were chosen for the custom capture panel to use
for downstream sequencing of 514 samples from 370 patients. The 2,697 list of genes were then
used to identify the genomic coordinates of all the exons and regions of interest desired to be
sequenced. Once identified, probes were designed to tile the regions of interest for use in a custom
hybrid capture reagent referred to as WUSM-LPv2 (Roche NimbleGen, Indianapolis, IN).

Clinical data clean-up leads to the inclusion and exclusion of samples from downstream
clinical analysis due to human errors. We first started off by ensuring that all sequencing data
processed had corresponding clinical data. Any sequencing data that did not have any clinical data
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was then traced back to its original submission form and checked for typos or if another sample
ID was used. We then reviewed each individual institute's clinical data for errors or missing data.
We used AMELY (y-linked), UTY (y-linked) and BTK (x-linked) as genetic representatives to
help verify the sex of the samples. Additionally, if a sample’s clinical data could not be reconciled
then the sample was simply excluded from any and all clinical data analysis but was included in
all genetic analysis. Any and all changes made to the clinical data due to error or changes for
reasons of harmonization were written into R code and uploaded to GitHub for version history
documentation (refer to Methods for detailed code).

Genetic pairwise correlation analysis identifies multiple sample misidentification events. All
515 samples (normal and tumor) from 371 patients were included in the genetic correlation
analysis. 66 samples from what was believed to be 47 unique patients were involved in unexpected
genetic correlations (SNP and sex analysis) and were resolved to only 21 actual unique patients
(Figure 2.1).
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Figure 2.1: Pearson correlation analysis of all sample VAFs to resolve the identity of unexpected
matches.
This correlation analysis was to initially confirm the relatedness of known samples, but resulted in the
identification of unexpected, related samples. All boxes are colored based on their Pearson correlation
coefficient from 0 (blue) to 1 (red).

A single patient had to have all samples removed from the study as their normal DNA sample
displayed signs of low-level contamination and no genetic correlation to what was labeled their
tumor RNA sample. The highest correlation achieved between the patient’s normal DNA and
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tumor DNA samples was 64% and our cut-off was 95%. The only samples that achieved a
correlation of ≥95% within this specific patient were their duplicated samples (Figure 2.2). This
patient’s samples were sequenced twice in an attempt to save their data hoping that contamination
occurred during the sequencing process; however, analysis of their second sequence made it clear
that contamination occurred directly to the storage sample and therefore could not be saved. This
is the only example of patient samples suffering from both a sample swap and contamination
within our cohort.

Figure 2.2: Pearson correlation analysis of sample VAFs to resolve the identity of LYM267.
LYM095 was confirmed to be unrelated to LYM267 and was included in this correlation analysis to be
used as an indicator of a true negative result. All boxes are colored based on their Pearson correlation
coefficient.
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According to our clinical records, samples FLX061, PH2028_tumor and PH2028_pc all originated
from the same male patient. However, during our initial genetic analysis to confirm the patient’s
sex, sample PH2028_tumor was predicted to be female. Upon further SNP correlation analysis we
discovered that none of the samples believed to be from the same patient shared any genetic
correlation (Figure 2.3). Two of the samples actually displayed an unexpected genetic correlation
of 98% to two other samples within the cohort that were not related to each other (Figure 2.3).
Sample PH2028_tumor’s SNPs and sex matched sample PH1988_tumor, while sample
PH2028_pc’s SNPs and sex matched sample FLX060. Therefore, sample FLX061 was determined
to be its own unique sample, sample PH2028_tumor was merged into sample PH1988_tumor and
sample PH2028_pc was merged into sample FLX060 resulting into the identification of 3 unique
patients.

Figure 2.3: Pearson correlation analysis of sample VAFs to resolve the identity of PH2028 and
FLX061.
LYM095 was confirmed to be unrelated to all other samples within this analysis and was included in this
correlation analysis to be used as an indicator of a true negative result. All boxes are colored based on
their Pearson correlation coefficient.
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The previously discussed sample swap and misidentification are the two main examples of what
we observed within our cohort. The genetic correlation analysis allowed us to accurately identify
which samples were related, but it also allowed us to identify samples that were presumed to be
related but displayed no correlation. For example, according to our clinical records, samples
080075255-1301334_1 (normal DNA), 080075255-1303352 (tumor DNA) and 080075255FLX032 (tumor DNA) all originated from the same male patient. All 080075255 sample sex
were verified except 080075255-1301334_1 as the sex could not be determined. Upon further
SNP correlation analysis, we confirmed that all of the samples believed to be from the same
patient shared a genetic correlation of ≥97% and an additional unexpected genetic correlation of
≥97% was found between all previous samples to sample FLX005 (tumor DNA) (Figure 2.4).
FLX005’s sex was recorded as Female, but our sex genetic analysis determined that the sample
is of Male origin which matches the other 080075255 samples’ sex. Therefore, sample FLX005
was determined to be a sample from patient 080075255 and had all their clinical data removed
from future clinical data analysis. This is a clear example of unexpected genetic correlation that
we were able to identify within our cohort.
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Figure 2.4: Pearson correlation analysis of sample VAFs to resolve the identity of 080075255 and
FLX005.
LYM095 was confirmed to be unrelated to all other samples within this analysis and was included in this
correlation analysis to be used as an indicator of a true negative result. This correlation analysis was to
initially confirm the relatedness of samples 080075255. All boxes are colored based on their Pearson
correlation coefficient.

Genetic correlations found when unexpected resolved between the following samples were: (1)
All LYM482 and PH1982, (2) All PH2020, 080075301, and PH1985_tumor, (3) All LYM235
and PH1977, (4) 080075174 and TFL001, (5) All LYM920 and FLX030, (6) FLX053 and
TFL005, (7) FLX057 and 080075031, (8) FLX058-2 and 080075260, (9) TF_UM8 and
TF_UM13, (10) 500174, 500175 and 500176, (11) 1029451 and 500106, (12) 250678 and
500119, (13) CCF022 and CCF122, (14) CCF024 and CCF119, (15) CCF027 and CCF117, (16)
CCF032 and CCF140, (17) CCF045 and CCF054, (18) CCF053 and CCF105, (19) CCF064 and
CCF084. Additionally, no genetic correlation found when expected resolved between the
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following samples were: (1) PH1985_tumor and PH1985_pc. The group that resulted in the most
samples swaps came from the Cleveland Clinic cohort. A total of 14 patient samples were
resolved to a total of 7 patients with 2 samples each.

Mutational landscape has been further confirmed and expanded from previous follicular
lymphoma studies. Since our initial analysis, we have completed sequencing of an additional 401
samples from 267 patients with clinical data available. We performed NGS sequencing on 147
fresh-frozen tumor samples with paired nonmalignant tissues from 69 patients: 1) We performed
exome plus WUSM-LPv1 capture sequencing on 52 fresh-frozen tumor samples with paired
nonmalignant (skin) tissue from 24 patients; 2) We performed exome sequencing on 30 freshfrozen tumor samples with paired nonmalignant (lymph node) tissue from 15 patients; 3) We
performed WUSM-LPv1 capture sequencing on 65 tumor samples with paired nonmalignant (skin)
tissue from 30 patients. Additionally, 275 tumor-only samples from 259 patients received WUSMLPv1 custom capture, while 92 tumor-only samples from 89 patients received WUSM-LPv2
custom capture sequencing. In total, 446 tumor samples (69 with paired normal samples) from 371
individuals were sequenced, achieving greater than 20x coverage for more than 75% of the targeted
region for all but seventeen samples (Figure 2.5). All general cohort sample attributes have been
summarized (Figures 2.6, 2.7, 2.8).
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Figure 2.5: Summarization of sequencing data coverage per cohort.
The top violin plot shows the proportion of targeted regions with ≥20x sequencing coverage within each
cohort. The bottom violin plot shows the average sequencing coverage within each cohort.
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Figure 2.6: Summarization of sample types (normal or tumor), sequencing reagent used and where
the sample originated from either a specific study or institute.
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Figure 2.7: General clinical attributes summarized for the cohort.
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Figure 2.8: m7-FLIPI attributes summarized for the cohort.
All 7 genes incorporated into the m7-FLIPI score were targeted by our capture design and were therefore
evaluable for our patients. The m7-FLIPI prognostic model stratifies patients into low-risk or high-risk
categories with respect to 5-year failure-free survival after first line immunochemotherapy and integrates
performance status, FLIPI score, and the mutation status of seven genes (EZH2, ARID1A, MEF2B, EP300,
FOXO1, CREBBP, and CARD11).
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A total of 3,256,548 variants were initially called by one or more variant callers (Methods). Then
variants were filtered out based on coverage data, transcript errors, and gnomAD allele frequency
cut-offs leaving 51,981 variants remaining. A panel of normal filters was applied using a
combination of a breast cancer and lymphoma panel of normal, this step left 45,199 variants to be
manually reviewed. Manual review is a very tedious and complex process as multiple variables
(e.g., variant allele frequencies, read depths, etc.) have to be taken into account as well as
incorporating information not considered by automated variant callers (e.g., overlapping paired
end reads, variants only supported by reads in a specific direction, poor alignment in areas of
mononucleotide repeat regions, etc.). During this process a well-trained manual reviewer has to
assign one of four variant calls to the variants under inspection: somatic (S), ambiguous (A), fail
(F) and germline (G) (Table 2.1). Additionally, manual reviews should always use manual review
tags whenever conducting manual review as they can help to explain the rationale behind the
manual review called made or even be used to note concerns about a variant (Table 2.1). About
25,000 variants were called somatic, about 5,000 variants were called ambiguous and the rest of
the variants were either called fails or were determined to be germline (either way, these variants
are removed) (Figure 2.9).
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Table 2.1: List and description of manual review calls and tags used to annotate variants.
Figure originally published in (Barnell et al., 2019).
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Figure 2.9: Manual review calls made for all variants and separated by cohort and reviewer.
The bar graphs display the total number of variants and are colored based on the manual review call made
for that specific variant. G is for germline, F is for fail, A is for ambiguous and S is for somatic.

Very few or no manual review tags were used at all when reviews called a variant germline or
somatic because manual review tags are typically used to identify sequencing patterns or artifacts
that commonly result in false positive variant identification. In total there currently exist 19 manual
review variant tags and typically at least one or more tags are used when failing a variant (Barnell
et al., 2019). The top three tags used when failing a variant within our dataset during manual review
were short insert (SI), short insert only (SIO) and multiple mismatch (MM) which is apparent in
the overall count (Figure 2.10), but even more strikingly obvious in the overall percentage (Figure
2.11). This pattern is commonly caused by sequencing degraded nucleic acids, such as formalinfixed paraffin-embedded samples, which give rise to SI and SIO because of high levels of DNA
fragmentation (Barnell et al., 2019; Yost et al., 2012).
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Figure 2.10: Manual review tags count used to call a variant.
The left bar graph plots the number of tags used on a variant, so variants with multiple tags are counted
more than once. The right bar graph only plots a single tag representative per variant and excludes variants
with no tags.
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Figure 2.11: Manual review tags percentage used to call a variant.
The top bar graph plots the percentage of tags used on a variant, so variants with multiple tags are counted
more than once. The bottom bar graph only plots the percentage of a single tag representative per variant
and excludes variants with no tags.
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Updated somatic mutation analysis and confirmation of recurrent gene mutations
After filtering to remove common variants and pipeline artifacts followed by extensive manual
review, the number of the number of nonsynonymous coding variants (including splice
donor/acceptor sites) per sample ranged from 2 to 316 (median, 43). Of the 3,131 affected genes
2,129 were mutated in more than 1 sample. We identified 92 genes that were significantly mutated
above background mutation rates (herein referred to as SMGs) within the custom capture space
(FDR < 0.01) (Figure 2.12).
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Figure 2.12: Significantly mutated genes in FL.
The frequency and type of mutations affecting 92 genes identified as significantly mutated in our cohort
using MuSiC analysis (FDR < 0.01, convolution test method) are displayed in each row. Columns represent
each sample in the cohort and are ordered by the presence of mutations in the most to least frequently
mutated gene. For genes with multiple mutations in a single patient, only 1 mutation type is shown with
priority order indicated in the legend from the highest priority at the upper left to lowest at the bottom right.
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A total of 54 novel SMGs were identified compared to our last study, all but one gene (DISP1)
was previously identified as mutated within the cohort but did not previously reach significance.
38/39 total genes previously identified as significantly mutated by Krysiak et al. were observed to
still be SMGs with the addition of the new samples. HIST2H2AC was the only gene that lost
significance with the addition of the new samples, but only by a small margin. However, three
previously identified histone genes (HIST1H2BO, HIST1H3I, and HIST2H2BE) rose to
significance with the addition of the new samples. Initially observed in our discovery cohort,
significant co-occurrence of histone family mutations within patients was observed (p=0.0001,
Figure 2.13). We verified these co-occurring mutations were not mapping artifacts caused by
homology. A total of 50 histone genes harbored at least 1 coding mutation across the cohort.

Figure 2.13: Histone gene mutations co-occur within individual patients with FL.
Coding and splice site mutations in genes encoding the core histones (H2A, H2B, H3, H4) or histone
linker (H1) often co-occur within patients. Each row represents a mutated histone gene, and each column
represents a patient in this cohort. Histone mutations per patient are displayed at the bottom, indicating
the total number of genes mutated (also summarized for the cohort in the bar graph on the left) and total
number of mutations observed (includes multiple mutations per gene). The distribution of mutations and
mutation types are indicated by colored boxes in the grid. For genes with multiple mutations in a single
patient, only 1 mutation type is shown, with priority order indicated in the legend from the highest
priority at the left to lowest at the right.
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Updated recurrent mutations in the B-cell receptor and CXCR4 signaling pathways
Frequency of mutations observed in the CXCR4 and B-cell receptor signaling pathways or the
SWI/SNF complex from the original cohort (N=105, black) and the expanded cohort (N=304,
blue). TNFAIP3, ARID1B, SYK, and BLNK were newly identified as significantly mutated in
the expanded cohort with an FDR<0.01 (blue outline) (Figure 2.14).

Figure 2.14: Frequencies of mutations affecting the BCR/CXCR4 signaling pathways and SWI/SNF
complex in patients with FL.
A) The interconnected BCR and CXCR4 signaling pathways are shown. Genes with nonsynonymous
coding or splice site mutations are depicted in green, with SMGs in dark green and the mutation
frequency observed in the original cohort (N = 105, black) and the expanded cohort (N=304, blue)
indicated. B) Recurrent mutations affecting both BAF (BRG1-associated factor) and PBAF (polybromo
BRG1-associated factor) SWI/SNF complexes were observed in our cohort and annotated as in A.
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2.3 Discussion
Recent large cohort publications (including our own (Krysiak et al., 2017)) provide a strong
foundation for the identification of important genes involved in the pathogenesis of FL. In our
opinion it is no longer safe to assume that patient overlap won’t occur within large cohort multiinstitute studies. Therefore, we suggest that genetic correlation analysis should initially be
conducted to verify no unexpected patient overlap exists as we observed that 13% (66/515) of
our samples resulted in unexpected genetic correlation matches. Additionally, it is not safe to
assume that samples being collected from the same institute with extensive clinical data history
and tissue bank logs can be excluded from genetic correlation analysis either. For example,
Cleveland Clinic samples resulted in the most sample swaps from within. We assume that these
sample swaps are a result of human reading and logging errors as a large portion of the samples’
identifiers are closely related. Some sample identifier numbers seem to be swapped or suffer
from being mistakenly entered during logging (e.g. CCF022 and CCF122, CCF045 and CCF054)
which could result in duplication of samples. Swap samples and misidentification can heavily
influence all downstream analysis and skew calculations.
Other extremely important factors that heavily influenced our data were the quality of our
samples, the quality of our sequencing data and the fact that the majority of our extension study
included tumor only samples. To comprehensively characterize the genomic landscape of FL we
require an extremely large cohort of samples to ensure we have fully covered our regions of
interest but obtaining large amounts of fresh samples in a timely manner is unrealistic. Therefore,
access to hundreds of archived samples of formalin-fixed paraffin-embedded (FFPE) material
presents a readily available resource that met our needs in a timely manner. Roughly 64%
(332/515) of our samples were unpaired FFPE samples. Unfortunately, FFPE samples are the
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least optimal to use when conducting next-generation sequencing as they can suffer from crosslinking, heavy DNA/RNA degradation, and fragmentation of DNA/RNA molecules which will
directly affect overall sequencing data quality (Cho et al., 2017; Esteve-Codina et al., 2017;
Gallegos Ruiz et al., 2007; X. H. Gao et al., 2020; Lehmann & Kreipe, 2001; Solassol et al.,
2011; Suciu et al., 2016). Seventeen samples were excluded due to low coverage as they did not
achieve greater than 20x coverage for more than 75% of the targeted region. Furthermore, we
believe that the nucleic acid degradation of FFPE samples caused a proliferation of shorter reads
(less than 300 base pairs) coupled with the increase of sequencing length achieved by nextgeneration sequencing (on average 150 base pairs) are directly responsible for the high number
of SI, SIO and MM manual review calls that resulted in variant failures. Additionally, tumoronly samples are notoriously difficult to work with because they suffer from increased false
positive variant calling as you do not have the patient’s normal sample to eliminate common
germline variation. Very little filtering is required when working with tumor-normal paired
samples from a patient because if the variant in question does not exist to appear in the normal
sample, then you can be confident the variant is somatic. However, tumor-only samples are
aligned, and variant calling is conducted compared to the human reference genome. Using the
human reference genome is extremely useful and significantly decreases the time it takes to place
a read alignment in context compared to de novo assembly. However, using the human reference
genome to conduct variant calling is problematic because humans on average differ by a little
less than 1% genomically (roughly 15 million nucleotides) and on average contain 5 million
single nucleotide polymorphisms (Keats & Sherman, 2013). Therefore, filtering out false
positives and identifying true positives required extensive knowledge on how to best filter and
call variants. We addressed the lack of normal paired samples by using a panel of normal breast
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cancer and lymphoma samples as a replacement to identify any potential variants found within
these samples to be excluded from the tumor-only samples. Additionally, we used gnomAD to
identify common SNPs within the population and excluded them from all tumor-only samples as
well. We believe that our data truly represents the FL genomic landscape due to our filtering
strategies and manual review.
The current extension study further increased the number of genes known to be mutated
in several previously described pathways and protein complexes. Our approach of using other Bcell malignancy studies in combination with a discovery data set to guide our capture design
worked well previously. As a result, we decided to simply extend this same approach and include
even more genes within our second custom capture to encapsulate. This design targets as many
genes as possible while maintaining a reasonable budget to allow us to sequence more samples.
This strategy allowed us to expand the genomic regions of interest targeted to increase our ability
to discover novel mutations associated with FL while also confirming our previous findings. 54
previously identified mutated genes rose to significance in our extension cohort bringing the total
of significantly mutated genes within our cohort to 92. All previous findings in our initial cohort
have been confirmed and extended. For example, we were able to identify new mutations within
the extended number of histone genes targeted in the new panel. Additionally, the frequency of
mutations affecting the BCR/CXCR4 signaling pathways and SWI/SNF complex in patients with
FL on average increased. However, this study is still an active work in progress and a lot of work
is still required to identify SMGs for the rest of the cohort, determine clinical correlations to
mutated genes and compare all of our findings to those to previous studies. So far, we were able
to successfully design an all-inclusive hybrid custom capture lymphoma panel derived from both
discovery sequencing and published reports in other B-cell malignancies, identified novel
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recurrent mutations in patients with FL, expanded the list of mutated genes in known FL
pathways, and confirm previously identified pathways associated with FL.
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2.4 Methods
2.4.1 Clinical data clean up
All clinical data changes and history of edits can be found on github located at
https://github.com/griffithlab/lymphoma/blob/master/FL_cohort2/Master_Clinical_Data_Cleanu
p.R and the code can be found in the appendix as the github repo is private. Briefly, the code
opens all clinical data files that were submitted to us and initially conducts universal changes to
ensure all files use the same notation system. Then code exists to make cohort specific alterations
to correct errors identified. Then we check to make sure that no obvious differences exist
between all cohorts, such as a missing column for treatment. We then merge all of the clinical
data and begin making universal adjustments to the entire cohort, such as binning NHL_type into
either the FL or t-NHL bin. We finally integrate and correct for all sample swaps/mix-ups by
changing the sample’s identifier and making a few other sample specific alterations.

2.4.2 SNP Genetic correlation analysis
A total of 2,435 common (minor allele frequency ≥1%) single nucleotide polymorphisms were
selected from dbSNP build 141 within the region of the smallest custom capture panel we
sequenced within our cohort. We extracted the genomic location for the common SNPs and
retrieved the variant allele frequencies (VAFs) for every location within each sample. We then
conducted Pearson correlation analysis on the VAFs for the entire cohort. A correlation of ≥95%
between normal DNA and tumor DNA samples was set as the cut-off if they originated from the
same patient as this was generally observed within our cohort. While a correlation of ≥57%
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between normal or tumor DNA samples and tumor RNA samples was set as the cut-off if they
originated from the same patient as this was generally observed within our cohort. Any correlation
below these thresholds signaled that the samples were not related.

2.4.3 Sequence data alignment and variant calling strategy
We performed sequence alignments and variant calling using the Genome Modeling System
(GMS). Paired-end reads were aligned to the human reference sequence GRCh37 using BWAMEM (version 0.7.10) and de-duplicated using Picard (version 1.46,
http://broadinstitute.github.io/picard/). Single nucleotide variants (SNVs) were identified using
SAMtools (versions 0.1.18), SomaticSniper (version 1.0.4), VarScan (version 2.3.6), MuTect
(version 1.1.4), Strelka (version 1.0.11), while insertions/deletions (indels) were identified using
Pindel (version 0.5), GATK, VarScan and Strelka. Variants were required to have a minimum
coverage of 25x counting only reads with a base and mapping quality of 20, minimum tumor
variant allele frequency (VAF) of 5% and at least 4 reads of support. Variants sequenced by the
custom capture panel were only kept if they were non-silent and within coding or splice site
regions, unless previously identified in the discovery samples cohort from the preliminary study
or within the targeted region surrounding BCL2. This step helped to make variant interpretations
easier, as we focused on protein coding changes. Common variants were removed if the minor
allele frequency was >0.001 in 1000 genomes, the Exome Sequencing Project, ExAC release 0.2
or gnomAD version 2.0.2. Additionally, all variants were filtered against exome sequencing data
from a panel of normal samples (N=905) from the TCGA breast cancer-sequencing project.
Variants were removed if they 1) have >3 variant reads and >2.5% VAF in 5 or more samples or
2) were identified by SNV/indel calling (SAMtools and VarScan) in 5 or more samples. Variants
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in transcripts annotated with “pseudogene”, “no start codon” or “no stop codon” and those on
unassembled contigs of the reference genome or mitochondrial regions were excluded from
further analysis. Then all variants were annotated as previously described using the GMS variant
annotator and reference transcript variants obtained from Ensembl v74.40. Finally, all variants
were subjected to visual inspection using IGV to remove sequencing and variant caller artifacts,
false positives (e.g., remaining germline variants) and other anomalies, and to flag variants of
questionable quality (e.g., occurring in repetitive regions or composed of read pairs with short
insert sizes).

2.4.4 Significantly mutated genes (SMGs) analysis
Significantly mutated genes were identified using MuSiC v0.4, with the false discovery rate
cutoff based on the convolution test method. The regions of interest were restricted to the exonic
regions and splice sites targeted by the custom capture reagent. A representative normal BAM
file was used for all unpaired extension samples. For individuals with multiple samples, variant
lists were merged. Mutual exclusivity and associated mutations were determined by permutation
analysis. The estimated P-value was determined using the number of permuted data sets with
more total co-occurring mutations than the real data set over 10 000 permutations.
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Chapter 3: Neoantigen Landscape Supports
Feasibility of Personalized Cancer Vaccine
for Follicular Lymphoma
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for Follicular Lymphoma. Targeted journal: Blood. 2021 March.
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3.1 Abstract
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment
for follicular lymphoma (FL). However, little is known about effective vaccine design informed
by high-throughput sequencing data. We set out to determine whether whole exome sequencing
(WES) and RNA sequencing (RNA-Seq) could infer a patients’ MHC Class I alleles, and
identify neoantigens and oligoclonal B-cells, to engineer personalized cancer vaccines.
Normal/tumor DNA and tumor RNA from 58 patients’ FL biopsies underwent WES and RNASeq. Potential somatic and B-cell clonotype neoantigens were predicted and filtered to identify
high quality neoantigens. B-cell clonality was determined by alignment of BCR CDR3 regions
from RNA sequence data, grouping at protein level, and comparison to BCR repertoire of
healthy individuals. An average of 52 short somatic mutations per patient (range: 2-172) were
identified. At least one high quality neoantigen was predicted for 56 out of 58 patients. Two or
more neoantigen candidates were identified for 55 (95%) patients with a mean of 16 predicted
peptides per patient (range: 0-38). 76% (702/905) of the total predicted neoantigen peptides arose
from missense mutations, 9% (81/905) from indels, 3% (25/905) from gene fusions and 11%
(97/905) from clonal B-cells. 78% (45/58) of patients have both somatic and BCR vaccine
candidates, while 19% (11/58) of patients had only somatic vaccine candidates. To our
knowledge, this is the first retrospective high-throughput sequencing analysis to evaluate the
neoantigen landscape and potential for personalized cancer vaccines as an alternative treatment
for FL patients. Based on these retrospective analyses we initiated a pilot trial using personalized
neoantigen vaccine therapy combined with PD-1 blockade on patients with relapsed or refractory
follicular lymphoma (NCT03121677). Long peptide vaccines were successfully synthesized for
all four patients enrolled to date. Initial results demonstrate feasibility, safety, and potential
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immunologic and clinical responses. This study suggests that FL patients would be candidates
for neoantigen personalized cancer vaccine clinical trials.
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3.2 Introduction

Follicular lymphoma (FL) is the most common indolent non-Hodgkin’s lymphoma,(Linet et al.,
2014; Project, 1997) however it remains incurable with conventional therapies(Kahl & Yang, 2016)
and is poorly responsive to checkpoint blockade as a single agent (Armand et al., 2020; Flowers
et al., 2018; Lesokhin et al., 2016). Since this lymphoma is indolent and standard therapy includes
chemotherapy with short- and long-term complications, a major emphasis in FL therapeutics is to
avoid chemotherapy in lieu of safer alternatives. The invention and the approval of rituximab to
treat FL in 1997 ushered in a new era of treatment resulting in prolonged survival without relapse
and an improvement of overall survival (Hiddemann et al., 2005; Maloney et al., 1997; Schulz et
al., 2007). However, since the improvements made by rituximab none of the currently available
immunotherapies alone and/or in combination with other standard treatments, further extend the
survival rate and they are not considered curative (Kirit M. Ardeshna et al., 2014; Kahl et al.,
2014). The majority of FL patients can be observed for several years without any significant impact
on their overall survival (K. M. Ardeshna et al., 2003). BioVaxID, a personalized idiotype cancer
vaccine, showed early promise as a new active immunotherapy to treat FL (Schuster et al., 2011).
However, BioVaxID contained only a single cancer target and recently failed to meet their primary
end points within a Phase III clinical trial (Freedman et al., 2009; Levy et al., 2014; Schuster et
al., 2011).
Personalized cancer vaccines represent a new form of active immunotherapy which aims
to cure FL patients by using their own immune system to eliminate their cancer. The mutational
processes that lead to lymphomagenesis and progression also produce neoantigens that can be
targeted by the immune system. Neoantigens are short, mutated peptide sequences ranging from
8 to 15 amino acids in length, resulting from somatic mutations that are specifically expressed by
tumor cells and not normal cells. Major histocompatibility complex (MHC) class I and/or II
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molecules have the ability to load and then display neoantigens to cytotoxic and/or helper T cells
for recognition and antitumor immune response (Chu et al., 2018; T. N. Schumacher & Scheper,
2019; T. N. Schumacher & Schreiber, 2015; Yarchoan et al., 2017). Reports of this approach
show promise within various forms of solid cancers (Anagnostou et al., 2017; Cohen et al., 2015;
George et al., 2017; Gros et al., 2016; Keskin et al., 2019; Koşaloğlu et al., 2016; Le et al., 2017;
Linnemann et al., 2015; Mennonna et al., 2017; Ott et al., 2017; Pritchard et al., 2015; Rizvi et al.,
2015; Robbins et al., 2013; Strønen et al., 2016; Tran et al., 2014, 2015; Wick et al., 2014) and
have only recently been briefly explored within a cohort of 53 FL patients using a small panel of
just 10 genes (Nielsen et al., 2016). Additionally, cancer specific B-cell receptors (BCR) could
also be targeted with a vaccine by identifying oligoclonal or polyclonal populations within the BCR
repertoire of patients (as done for BioVaxID). We hypothesized that a combined approach utilizing
both oligoclonal and polyclonal BCR populations, small somatic mutations and gene fusions,
could provide a comprehensive active immunotherapy specific for FL patients, and ultimately
improve outcomes.
FL has a low to medium mutation burden (Alexandrov et al., 2013; Lawrence et al., 2013).
A recent FL publication by Krysiak et al. 2017 identified an estimated median of 55 somatic coding
mutations (range, 2-169) per individual meaning that on average an individual could have up to
55 potential vaccine candidates (range, 2-169). However, the question remains how many of
these somatic mutations could actually represent high quality neoantigens. It should be noted that
only a weak correlation exists between mutation burden and response to immune therapies while
other studies have shown relatively few immunogenic neoantigens are necessary for a detectable
response (Nielsen et al., 2016).
The feasibility of the neoantigen vaccine approach and precisely how to optimize effective
vaccine design informed by next-generation sequencing data is not fully understood (Richters et
al., 2019; Wells et al., 2020). It is equally unclear what factors may contribute to the success or
failure of personalized cancer vaccines. Here we report on the feasibility of vaccine design in FL
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using a comprehensive approach. We applied whole exome (WES) and RNA sequencing (RNASeq) to a cohort of 58 FL patients, performed mutation calling, HLA typing, BCR clonotyping,
fusion calling, neoantigen prediction, and in silico vaccine design (Figure 1). We also investigated
the application of this strategy in a pilot clinical trial utilizing personalized neoantigen vaccine
therapies in combination with PD-1 blockade for patients with relapsed or refractory follicular
lymphoma.
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Figure 3.1: Overview of the FL personalized cancer vaccine pipeline
First, patient samples are acquired and then sequenced (top left). Somatic variants of various types,
including single nucleotide variants (SNVs; blue), deletions (red), insertions (green), and fusions (pink),
are predicted. Sequence data are analyzed to determine human leukocyte antigen (HLA) types and B-cell
clonotypes for each patient. Variant and clonal B-cell peptide sequences are inferred from variants and
analyzed with respect to their predicted expression, proteasome processing, and ability to bind the patient’s
MHC Class I complexes. Candidates are then selected for vaccine design and additional analyses are
performed to assess manufacturability. Bioinformatic tools used for each step are indicated in italics.
Abbreviations: BCR, B-cell receptor; CDR3, complementarity-determining region 3; IEDB, Immune
Epitope Database.
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3.3 Results
Mutational landscape resembles that of previous follicular lymphoma studies. To identify
high quality personalized cancer vaccine candidates in FL, we performed WES of 58 fresh-frozen
tumor samples with paired non-malignant (skin or blood) tissue from 57 patients (one patient had
both diagnosis and relapse samples). Additionally, we performed tumor RNA-Seq for 57 of these
fresh-frozen tumor samples (LYM520 RNA sample failed QC assessment). In total, our cohort
included 27 patients with treatment-naive FL (3 with flow-sorted cells), 22 with relapsed disease
(2 with flow-sorted cells), 8 with transformed FL and 1 with composite HL/FL (Table 3.1).
Characteristics

Genetic analysis values

Total number of patients

58

Female, %

46

Male, %

54

Age (Median)

53

Age range

22-77

Stage, %
I

12

II

5

III

36

IV

47

FLIPI score, %
Low

36

Intermediate

26

High

35

NA: no information

3

Lymphoma type, %
FL

84

Transformed lymphoma (tNHL)

16

Sequenced biospy, %
Treatment-naïve FL

47

Relapsed FL

38

Transformed lymphoma (tNHL)

15

Table 3.1: Summary of clinical characteristics of patients used for genetic analysis
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The performance of bulk fresh frozen samples was sufficient for analyses achieving >20X
coverage for >75% of the targeted region for all tumor and normal WES samples with a mean
coverage of 76X. An average of 145 million total reads (range: ~48-545 million) were sequenced
per patient for RNA-Seq samples; of those total reads an average of 67.3% of reads mapped (range:
36-98%). Additionally, the breakdown of average percent of aligned bases was: 6.3% ribosomal
(range: ~0-45%), 11.3% UTR (range: ~9-27%), 5.7% intronic (range: ~1-42%), 0.9% intergenic
(range: ~0-7%) and 75.9% coding (range: ~14-87%). After filtering to remove common variants
and pipeline artifacts, the number of nonsynonymous coding variants (including splice
donor/acceptor sites) per sample ranged from 2 to 172 (mean 52; median 36). Of the 1,787 affected
genes, 264 were mutated in more than 1 patient. Thirty-two out of 39 genes that were previously
identified as significantly mutated by Krysiak et al.(Krysiak et al., 2017) were also found to be
mutated within our cohort. In our cohort, many genes with established relevance to FL were
recurrently mutated (KMT2D/MML2 [67%], CREBBP [41%], TNFRSF14 [41%], BCL2 [36%],
ATP6V1B2 [16%], STAT6 [12%], EZH2 [10%], IRF8 [10%], CD79B [10%], BCL7A [9%],
EP300 [9%], MEF2B [9%], CARD11 [7%], TP53 [7%], and GNA13 [7%]; Figure 3.2).
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Figure 3.2: Recurrently mutated genes and mutation burden observed for all patients
The bar graph on the top corresponds to the number of total mutations per patient and is colored by mutation
type. The bar graph on the left corresponds to the percentage of mutations for a given gene for the entire
cohort. Columns represent each patient in the cohort and are ordered by the presence of mutations in the
most to least frequently mutated gene. The main plot indicates the presence or absence of a mutation for
each patient and gene combination, colored by mutation type. If a patient has multiple mutations for an
individual gene, it is colored according to the priority order as indicated in the mutation type legend, from
top to bottom. A white star indicates which mutations are predicted to result in high quality neoantigen
vaccine candidates.

Many individuals harbored more than 1 KMT2D mutation with 57 mutations observed in 39
individuals and more than 1 BCL2 mutation with 31 mutations observed in 21 individuals. No
obvious hotspot mutations were identified within any genes within the cohort. Additionally, 40%
(23/57) of the cohort harbored unique fusion genes (Figure 3.3).
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Figure 3.3: WashU manually reviewed fusion genes waterfall plot
The bar graph on the top corresponds to the number of total fusions per patient and colored by fusion type.
The bar graph on the left corresponds to the percentage of fusions for a given gene for the entire cohort.
Only a single fusion transcript pair is recognized per gene pair even if a patient has multiple fusion transcript
pairs within that fusion.
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The most recurrently identified fusion gene pair was ARL17A--KANSL1 found within 4 patients.
However, BCL6 was also involved in fusions with different gene partners occurring within 4
patients. Genes such as CREBBP, POU2F2, CD74, IRF4, and KLF2 known to be involved in FL,
were also identified as gene fusion pairs within our patient cohort.

B-cell normal and tumor clonality analysis identifies oligoclonal and polyclonal populations.
To investigate B-cell clonal composition in normal lymph nodes we collected publicly available
RNA-Seq data of B-cell enriched samples (Chen et al., 2018; Dvinge et al., 2014; Dvinge &
Bradley, 2015; Ferreiro et al., 2014; Lonsdale et al., 2013; Madan et al., 2015; Mo et al., 2018;
Shchetynsky et al., 2017; Visconte et al., 2012). In total 53 such samples had sufficient sequencing
coverage of the BCR in RNA-Seq data and thus were further analyzed. Comparison of the
reconstructed BCR repertoire revealed strong differences between these normals and the malignant
(FL) samples (Figure 3.4,3.5).
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Figure 3.4: Clonality analysis of B-cell receptor populations within healthy normal samples and
follicular lymphoma samples.
Panel (a) depicts immunoglobulin heavy (IgH) chain coverage and fraction of clonotype groups where
major clonotypes ≥9% are designated with blue. Panel (b) depicts immunoglobulin kappa (IgK) chain
coverage and fraction of clonotype groups where major clonotypes ≥9% are designated with orange.
Panel (c) contains immunoglobulin lambda (IgL) chain coverage and fraction of clonotype groups where
major clonotypes ≥9% (dotted line) are designated with green. Stars below each panel indicate those
major clonotypes predicted to result in one or more high quality neoantigen vaccine candidates.
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Figure 3.5: Comparative healthy and malignant B-cell repertoire
a. Overall RNA-Seq coverage was good (>50M reads) for all the cohorts of both healthy/normal and
tumor (FL) samples. B. BCR clonality evaluated individually by heavy, kappa and lambda chains
repertoire are much higher in tumor samples for all the chains. c. Prevalent clonotype in tumor samples
has also much higher content compared to normal samples being evaluated for all three chains.
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While most FL samples had high clonality by NGS methodology (median IgH clonality = 0.25)
with a single or few dominant clone(s), almost all normal samples showed low clonality (median
IGH clonality = 0.04). A threshold for a dominant clonotype group content of 9% was used as a
cut-off value to identify a likely malignant population. Among the normal samples, only two had
a dominant clonotype exceeding the selected cut-off for a heavy chain while most (78%) FL
samples had a likely malignant clonotype group over the 9% cut-off. Light chain analysis was
performed separately for both light chains. Kappa and lambda light chains revealed similar
landscapes: normal samples lacked explicit dominant clonotype groups for both chains while FL
samples generally had one dominant clonotype.
Small somatic mutations (SNVs and indels) and gene fusions are common forms of cancer
variants that have the potential to become neoantigens in all cancers. However, FL is also an
oligoclonal or polyclonal B-cell malignancy with each patient’s tumor expressing a unique cell
surface BCR. Previous research has shown that B-cell lymphomas selectively retain expression of
the BCR for survival (Küppers, 2005). This means that additional tumor-specific neoantigen
candidates exist specifically for FL patients derived from the immunoglobulin heavy (IgH) and/or
light/kappa (IgL/K) chains which make up BCRs. The average number of total clonotypes (IgH,
IgL and IgK) detected within each patient’s BCR repertoire was 1,400 (median: 550, range: 2022,052). An average of 361 unique IgH clonotypes (range: 6-7,762) and an average of 770 unique
IgL/K clonotypes (range: 6-10,029) were identified. A total of 59 out of 20,244 (0.3%) unique IgH
clonotypes and 57 out of 43,918 (0.1%) unique IgL/K clonotypes were found to be clonal or
subclonal. A total of 118 unique clonal BCRs (mode: 2, range: 0-6) were identified (Figure 3.6a,
b, d). An average of 5,083 reads (range: 136-76,742) were used in clonotyping each patient’s BCR
repertoire (Figure 3.6c).
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Figure 3.6: B-cell tumor repertoire oligoclonality analysis identifies oligoclonal and polyclonal
populations within follicular lymphoma patients.
Heatmaps of B-cell Receptor repertoire clonality for (a) Immunoglobulin heavy chain (IgH) and (b) for
Immunoglobulin light/kappa chain (IgL/K) were generated by MiXCR and include only FR3, CDR3 and
FR4 regions. Clonotype clonal fractions are displayed as colours ranging from white to purple as shown
in the key. Only the first 5 major clonotypes are included for all patients and the entire cohort is sorted by
IgH clonality. (c) The total number of reads used in clonotype generation. (d) The total number of BCR
vaccine candidates predicted per patient.
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The average number of independent supporting reads per clonotype was 4 (range: 1.59-13.34).
From the total 57 patients with RNA-Seq data available, 46 patients had at least one clonal IgH
and IgL/K clonotype, 2 patients had IgL/K clonotypes only, 1 patient had IgH clonotypes only,
and 8 had no clonal IgH or IgL/K clonotype.
Interestingly, 17 patients had two or more dominant IgH and/or IgL/K clones. Of these,
only one patient had multiple IgH and IgL/K clones, 7 had multiple IgH clones and 9 had multiple
IgL/K. We wanted to understand if any of these cases of multiple dominant clones displayed
subclonal architecture when compared to each other. We performed pairwise nucleotide and
protein sequence alignment between all dominant clones within a patient’s BCR repertoire. As
expected, dominant clones with the same VDJ alleles were found to have greater sequence
similarities when compared to dominant clones with different VDJ alleles. For example, LYM720
had four dominant clones (25%, 23.8%, 17.3% and 12.7% of IgH clonality) and 3 of the clones
share the exact same VDJ alleles with their best alignment score percentage to each other ranging
from 92.9 to 97.9% (Table 3.2).
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Table 3.2: Pairwise protein sequence alignment for patients with multiple major IGH clones
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However, when all three of these dominant clones are compared to the fourth clone with a differing
VDJ allele, they only achieve a best alignment score percentage of 48.8%. We theorize that
LYM720’s clone1 is the founding clone, clones 2 and 3 are both subclones of clone1, while clone4
is a novel clonal expansion as it shares little sequence similarity to the other clones. The same
patterns can be observed for patients with multiple IgL/K dominant clones (Table 3.3).
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Table 3.3: Pairwise protein sequence alignment for patients with multiple major IGL/K clones
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After manual review of the clonotype pairwise protein sequence alignment data we concluded that
5 patients have a founding and sub clonal relationship as previously described. However, the other
5 patients found to have multiple related clonotypes based off of the pairwise protein sequence
alignment contain two novel clones with no relation to each other. Patient sample LYM120_t had
two major IgL/K dominant clones identified occurring at 42.1% and 18.6% that displayed high
CDR3 protein sequence homology only differing by a total of 2 amino acid positions to clones
below the 9% cut-off (Table 3.4).

Table 3.4: Pairwise nucleotide sequence alignment for LYM120_t with multiple major IGL clones.
The table contains the 9 most abundant B-cell clonotypes and the highlighted nucleotide colors indicate
whether a nucleotide matches the majority of the alignment (orange) and if a mis-match exists (red).
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Upon further inspection the major IgL/K dominant clones also displayed high CDR3 nucleotide
sequence homology to each other only differing by a total of 4 nucleotide positions. We believe
that Ig somatic hypermutation likely accounts for the clonal architecture we observed within our
cohort (Figure 3.7).

Figure 3.7: Pairwise nucleotide sequence alignment graph.
Each circle graph represents a patient’s entire B-cell repertoire and if B-cells are subclones determined
via alignment they are linked through blue lines.

At least one high quality personalized neoantigen cancer vaccine candidate was predicted
for all but two patients (97%). The feasibility of this approach and precisely how to optimally
identify personalized neoantigen cancer vaccine candidates informed by next-generation
sequencing data remains an unanswered question (Richters et al., 2019; Wells et al., 2020). Two
parallel analyses were conducted using the same raw sequencing data to determine what
potential factors may contribute to the identification of predicted high quality neoantigen cancer
vaccine candidates. The WashU analysis pipeline (Methods) considered all small somatic
mutations, gene fusions and BCR dominant clones that passed filtering criteria and manual
inspection as neoantigen candidates (Methods). This resulted in a total set of 3,065 small
somatic variants (median: 46, mean: 52, range: 2-172) (Figure 3.8).
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Figure 3.8: Personalized neoantigen cancer vaccine identification and prioritization filtering steps.
Swarm plots display the number of vaccine candidates on the y-axis for the entire cohort at each stage of
filtering (x-axis), moving from left to right.

These mutations are considered high quality tumor specific variants. However, not all tumor
specific variants are potential neoantigens. Small silent somatic mutations were filtered out
leaving a total of 2,399 mutations (median: 36, mean: 41, range: 1-138). Then candidates with a
normal variant allele frequency (VAF) greater than one percent were filtered out to ensure all
remaining 1,301 candidates (median: 20, mean: 22, range: 1-62) were highly tumor specific.
Next we filtered out any mutations with a predicted median ic50 binding affinity greater than
500 (Note: we computed peptides of sizes 8-11, with a sliding window around the mutation,
using a number of binding prediction algorithms, and then calculate a median binding affinity)
leaving a total of 1,087 candidates (median: 16, mean: 19, range: 0-53). Our last filter was
focused on ensuring that the tumor specific mutations are actively being expressed (transcribed)
thus creating the potential for the mutation to be translated to protein, bound, and displayed on
the cell surface by MHC Class I molecules, leaving a total of 783 predicted high quality
neoantigen small somatic candidates for the entire cohort (median: 12, mean: 14, range: 0-36)
(Figure 3.8). We observed a correlation between the number of manually reviewed small
somatic mutations and the number of predicted small somatic high quality neoantigen vaccine
candidates (R2 = 0.6464) within our cohort (Figure 3.9, 3.10).
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Figure 3.9 Correlation between the number of short somatic mutations (SNVs and Indels) and the
number of predicted high quality neoantigen candidates.
The x-axis displays the total number of predicted high quality neoantigen candidates per patient. The yaxis displays the total number of manually reviewed short somatic variants (SNVs and Indels).

Figure 3.10: Total number of somatic mutations resulting in vaccine candidates.
The bar graphs depict the numbers of final neoantigen vaccine candidates for each patient, colored
according to source (SNV, indel, BCRs, fusions) and are sorted from least to most total candidates and
includes failed neoantigen candidates that did not pass filtering.
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Peptides suitable for cancer vaccine generation were identified for all but two patients (97%) from
our cohort and 55/58 (95%) patients had multiple (at least two) vaccine candidates (Figure 3.11).

Figure 3.11: The vaccine candidate landscape per patient.
The bar graphs depict the numbers of final neoantigen vaccine candidates for each patient, colored
according to source (SNV, indel, BCR, fusion) and are sorted from least to most total candidates. The red
line in the graph depicts the minimum cutoff of 2 candidates required for potential vaccine design.

These predicted high quality neoantigens include those which arose from genes known to be
recurrently mutated in FL as well as from presumed passenger mutations. These genes include but
are not limited to KMT2D/MML2 [25% mutation rate in this cohort], BCL2 [20%], CREBBP
[18%], IGLL5 [11%], STAT6 [6%], IRF8 [6%], TNFRSF14 [4%], POU2F2 [4%], PIM1 [4%],
MEF2B [4%], 12 unique HIST genes [4%], GNA13 [4%], and CD79B [4%]. This suggests that
key known FL driver genes may play an important role in neoantigen vaccine design (Figure
3.12).
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Figure 3.12: Recurrently mutated genes and mutation burden observed for all predicted high
quality neoantigens.
The bar graph on the top corresponds to the number of total mutations per patient predicted as high
quality neoantigens and colored by mutation type. The bar graph on the left corresponds to the percentage
of mutations for a given gene for the entire cohort. Columns represent each patient in the cohort and are
ordered by the presence of mutations in the most to least frequently mutated gene. Only a single mutation
is recognized per gene even if a patient has multiple mutations within that gene, priority order is indicated
in the legend from top to bottom.
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Additionally, 40% (23/57) of the cohort harbored unique fusion genes (Figure 3.3). A total of 25
gene fusions (mean: 2, range: 0-4) were predicted to be high quality neoantigen vaccine candidates
within 25% (14/57) of the entire cohort (Figure 3.11,3.13).

Figure 3.13: WashU predicted high quality fusion neoantigen vaccine candidate waterfall plot.
The bar graph on the top corresponds to the number of total fusions per patient and colored by fusion type.
The bar graph on the left corresponds to the percentage of fusions for a given gene for the entire cohort.
Only a single fusion transcript pair is recognized per gene pair even if a patient has multiple fusion transcript
pairs within that fusion, priority order is indicated in the legend from top to bottom.
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From the total 57 patients with RNA-Seq data available, 46 patients had at least one clonal IgH
and IgL/K clonotype, 2 patients had IgL/K clonotypes only, 1 patient had IgH clonotypes only,
and 8 had no clonal IgH or IgL/K clonotype (Methods). In total, 22% (26/118) of the BCR
clonotypes identified as dominant clones included short peptide sequences which were predicted
to sufficiently bind to their respective MHCs (500 < ic50 binding affinity ≤ 1,000), while 60%
(71/118) included short peptide sequences which are strong binders to their respective MHCs (ic50
binding affinity ≤ 500) (Figure 3.14). A total of 97 clonal BCRs (mode: 2, range: 0-6) were
predicted to be high quality neoantigen vaccine candidates representing 79% (45/57) of the entire
cohort (Figure 3.11, 3.6d).
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Figure 3.14: Heatmaps of best median IC50 score for major clonotypes for IgH and for IgL/K.
Scores were generated by the pVACtools pVACbind module using trimmed regions of FR3 and FR4 which
span CDR3. The median IC50 scores are displayed as colours ranging from red to blue as shown in the key.
Protein sequences with a gap or stop codon were excluded entirely. Only the first 5 major clonotypes are
displayed for all patients and the entire cohort is sorted by IgH clonality.
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Two or more neoantigen candidates were identified for 95% (55/58) patients with a mean of 16
predicted peptides per patient (range: 0-38). Overall, 76% (702/905) of the total predicted patient
peptides arose from missense mutations, 9% (81/905) from indels, 3% (25/905) from gene fusions
and 11% (97/905) from clonal B-cells. Furthermore, 97% (56/58) of patients have at least one
missense or indel somatic vaccine candidate, 25% (14/57) of patients have at least one fusion
vaccine candidate, 79% (45/57) of patients have at least one B-cell vaccine candidate, a single
patient had no vaccine identifiable candidates. The method used in the BostonGene Vaccine
Module was partially complementary to those of WashU’s analysis pipeline (Methods). Overall,
the BostonGene Vaccine Module yielded fewer neoantigen candidates. This was expected due to
a more conservative approach which required more mutant transcripts to be captured by RNA-Seq
(Table 3.5). 21% of vaccine candidates predicted were shared out of the total 1,179 collectively
predicted vaccine candidates from the modules. For over 76% of samples a set of common
neoantigens were generated by both approaches (Figure 3.14).
Patient
LYM013
LYM139
LYM1032
FLNA-02
LYM005
LYM013
LYM023

Fusion
ARHGEF18--CD320
PTPRC--NBPF14
RMDN2--ALS2
KLF2--POU2F2
MTG1--SMAD7
CNN2--PPP1R12C
ELK3--CDK17

Epitope
Affinity, nM
HLA allele
VLYGTNEIL
208.02
A02:01
FLDTEVFVTV
5.97
A02:01
GGFPQALKK
158.48
A11:01
HLRTHTEIR
56.46
A31:01
KQIPNFFWSL
75.88
A02:01
ALAGKLRNQK
49.8
A03:01
YYYDKSLLX
19.49
A29:02
KAADESERTQ
LYM045
TPM4--CTD-2192J16.20
64.79
B57:01
W
LYM058
CAPZA2--DYRK1A
EEKVIVLPL
164.23
B40:01
FLNA-02
BANK1--PPP3CA
SLFHFLQV
112.77
A02:01
FLNA-04
CTDSP1--DNM3OS
VVHQVLHTR
108.25
A68:01
LYM033
DUSP28--PASK
QLLELEAWQL
56.04
A02:01
LYM1322
CEP350--RC3H1
LLLRLQQEKV
352.52
A02:01
LYM677
BANK1--PPP3CA
GPAPPAVPF
26.3
B07:02
LYM677
CPSF6--CHMP1A
ESANIVIVRR
9.57
A68:01
LYM677
DNAJC10--ANKRD44
FYERAKPPL
123.91
C07:02
Table 3.5: BostonGene predicted high quality fusion neoantigen vaccine candidates
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Figure 3.15: Predicted high quality neoantigen predictions and comparison between WashU and
BostonGene analysis pipelines.
Concordance of complementary approaches for neoantigen prediction. The bar graph shows the number
of neoantigens unique to and shared between the WashU analysis pipeline and the BostonGene Vaccine
Module V1 pipeline.

Antigen presenting machinery abnormalities should be taken into account to ensure
neoantigen presentation. Neoantigens are recognized by antigen-specific T cells through MHC
complexes composed of HLA alleles on the tumor cell surface, thus making HLA expression an
important antitumor immune response factor necessary to analyze in FL samples (Figure 3.15).

Figure 3.16: MHC Class I and II patient expression profiles.
Median transformed log2(TPM+1) RNA expression levels of MHC Class I and II genes
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Downregulation of HLA genes can hamper antigen presentation and subsequent vaccination
efficacy. Therefore, we evaluated HLA genes expression for all considered samples. It revealed
that some samples had low expression of class I genes (e.g., LYM395, LYM760 and LYM1071)
while some others had depressed class II expressions (e.g., LYM228, LYM1376 and LYM235).
In addition to analysis of major histocompatibility complex RNA expression we also investigated
mutations in genes of antigen processing and presenting machinery (APM) (Figure 3.17).

Figure 3.17: Antigen processing and presentation machinery mutations.
Somatic mutations in antigen presenting machinery genes. Only 7 mutated genes of total 32 APM genes
considered.

Most samples had no mutations in APM genes, or had missense variants of unknown significance,
we identified two samples bearing likely loss of function mutations in APM. A novel frameshift
insertion in the β2 microglobulin (B2M) gene was observed in the beginning of the transcript
(p.Ala6ArgfsTer52) of LYM1376. Another likely loss-of-function (nonsense) variant was found
in the tapasin gene (TAPBP) in LYM730. Somatic mutations in major histocompatibility
complexes were also investigated though no nonsynonymous mutations were found.

Molecular functional profiling of tumor microenvironment
Next, we dissected the tumor microenvironment by evaluation activity of its key cellular
components and processes (Figure 3.18). This profiling revealed three explicit clusters following
a subset of earlier established ones for DLBCL: “depleted” with low activity and abundance of
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tumor microenvironment, “mesenchymal” with stromal cells and activation of extracellular matrix
pathways and “immune active” with activation of several T-cell phenotypes in lymph nodes
(Figure 3.18).

Figure 3.18: Molecular functional profiling of samples in the cohort.
Molecular functional profiling by a set of gene expression signatures dissecting tumor microenvironment.
Cell color depicts median transformed ssGSEA score for selected signature.

Clonality analysis showed that most FLs are heterogenous and subclonal architecture
should be considered in vaccine design. To investigate the clonal architecture of the 58 FL
patient’s tumors within our cohort we identified subclones by clustering the VAFs from copy
number neutral, LOH-free, non-repetitive regions of the genome using SciClone. The average
variant read depth for the cohort was 186 (range: 20-3,225). The average variant read depth per
patient was 173 (range: 60-554) and only three patients had an average depth below 100x
coverage (Figure 3.19). The average VAF for the cohort was 24 (range: 3-93). The average VAF
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per patient was 23 (range: 7.6-40.9) (Figure 3.20). The average number of tumor clonal
populations identified per patient was 3 (mode: 2, range: 1-6) (Figure 3.21).

Figure 3.19: Clonality Read Depth.
Boxplots of each individual patient read depths for all manually reviewed variants within that patient.
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Figure 3.20: Clonality DNA VAF.
Boxplots of each individual patient tumor DNA VAF for all manually reviewed variants within that
patient.
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Figure 3.21: Inferring subclonal architecture objectively in follicular lymphoma patients.
Each patient’s SciClone plot is made up of two graphs: 1) Kernel density plots of VAFs across regions
with copy number two, posterior predictive densities summed over all clusters for copy number neutral
variants, and posterior predictive densities for each cluster/component and 2) Clusters detected using
variants from copy number neutral segments.

99

A pilot clinical trial demonstrated safety and feasibility of a neoantigen vaccine together
with checkpoint blockade in FL. Based on results of the retrospective analysis, we initiated a
pilot trial (IRB and FDA IND-approved, open to accrual, NCT03121677) using personalized
neoantigen vaccine therapy (as described above and in methods) combined with PD-1 blockade
on patients with relapsed or refractory FL (Methods; Figure 3.22,3.23).

Figure 3.22: Clinical trial treatment schema (#NCT03121677)
Treatment schema showing Day, Week, and Cycle of all staging, treatment biopsy, blood, draw, and
leukapheresis events. Note that rituximab is only administered if the patient experiences progressive
disease while awaiting vaccine study therapy.
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Figure 3.23: Overview of pilot trial to evaluate neoantigen vaccine + ICT in FL
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To date, four patients were enrolled and received vaccine plus nivolumab. Multiple unique highquality tumor specific mutant antigens (12-19 per patient) were identified in 4 of 4 pretreatment
biopsies. Long peptide vaccines were successfully synthesized for 4 of 4 patients. For each
patient, approximately 20 peptides were pooled into 4 groups of 5 with the goal of minimizing
competition for the same Class I molecule with each of the 4 pools administered in a different
limb. The time from biopsy to treatment ranged from 5 to 7 months and all patients were able to
be safely observed until administration of the vaccine. This time frame reflects initial challenges
related to establishing our pipeline; a turn-around of <3 months is targeted for future cases. There
were no grade 3-5 adverse events and only rare grade 1-2 events: most commonly injection site
reactions. Responses post cycle 2 (C2) included 1 complete remission, 1 stable disease and 2
progressive disease. The 2 patients with progression received 4 weekly doses of rituximab per
protocol; one achieved a partial remission and one a complete remission following rituximab,
and both continued on study with vaccine, nivolumab and 4 additional doses of maintenance
rituximab.

Immunologic response studies showed that neoantigens induced a cellular immune response
in a follicular lymphoma patient. In a patient with complete remission, we completed initial
immunological response studies (Figure 3.24). For this patient, we identified nineteen predicted
high quality neoantigen vaccine candidates using pVACtools (Table 3.6).
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Figure 3.24: Summarized clinical trial overview and timeline for patient FLNA-04 (See Figure 3.21
and 3.22 for more detailed versions).

Table 3.6: FLNA-04 list of vaccine candidates selected
The table lists all variants that were predicted to result in high quality neoantigen vaccine candidates along
with corresponding HLA allele, selection criteria, long peptide sequence submitted, synthesis success
status, and vaccination pool. Short epitope sequences that binding predictions were based on are bolded
within the long peptide sequences submitted.
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A total of sixteen peptides were formulated into a synthetic long peptide (SLP) vaccine consisting
of thirteen peptides predicted to bind to HLA-A*68:01 and/or five peptides predicted to bind to
HLA-A*23:01. A total of 9 unique HLA-A*68:01 candidate short peptides were screened on a
newly created TAP(-) cell line to determine if the algorithm-predicted neoantigen could bind and
stabilize its cognate Class I MHC molecule. Four neoantigen candidates stabilized HLA-A*68:01
as predicted in a dose dependent manner (3 of 4 positives shown, HIST1H2BK A111X, ZNF100
I218V and BCL2 A4T, Figure 3.25).

Figure 3.25: Peptide stabilization of selected candidate neoantigens.
Various concentrations of peptides were incubated overnight with ICP-47 expressing (TAP deficient) B
cell line expressing HLA A*68:01 heavy chain, washed and then stained with W6/32 APC. MFI of cells
pulsed with decreasing peptide concentrations were compared to no peptide pulsed control cells to validate
predicted peptide stabilization of MHC Class I molecules.
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The long peptides used to vaccinate the patient were used to stimulate and expand peripheral blood
mononuclear cells (PBMC) from the patient four months after the initiation of the vaccine and
probed for IFN-g expression by standard ELISPOT. The quantification of spots was collected
blindly, and images of triplicate wells are shown (Figure 3.26).

Figure 3.26: ELISPOT confirmation of T-cells reactive to long peptide vaccination.
PBMC from cycle 6 apheresis were pulsed with vaccinating peptides and cultured for twelve days in vitro
and then challenged with predicted short peptides overnight on IFN-g coated ELISPOT plates. Bar graph
shows triplicate value spots per million PBMC from D12 culture.
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The greatest response was shown to HIST1H2BK A111X (1,282 +/- 30 SPU/1e6 PBMC) while
the other two candidates ZNF100 I218V and BCL2 A4T showed 573+/-35, and 566+/-70
SPU/1e6 PBMC, respectively. Both of the latter candidate SPU were above the negative control
peptide CITF D459G 278+/-50 SPU/1e6 indicating a positive IFN- response. To determine if
circulating antigen specific CD8 T cells could be detected in post-vaccinated PMBC, MHC Class
I tetramers were prepared with the three candidate peptides shown to be enriched by ELISPOT
and used to probe ten day, LP stimulated PBMC. 0.5% of the CD8 T cells are specific for
HIST1H2BK A111X PE/APC tetramers and are greater than the negative control CITFD459G
negative control (Figure 3.27).

Figure 3.27: Circulating antigen specific CD8+ T-cell found reactive to HIST1H2BK A111X.
An example positive antigen specific Cytotoxic T lymphocytes (CTLs) enrichment detected by peptide
loaded tetramers stained with Tetramer PE and Tetramer APC gated on live, CD3/CD8DP CTLs from
D12 CTLs.
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Lastly, IFN- and TNF- expression from CD8 T cells is a hallmark of enhanced effector function
(Bhat et al., 2017). Ten day, post vaccine PBMC cultures stimulated with HIST1H2BK A111X,
LP and then re-stimulated with AAPC loaded with candidate SP, revealed CD8 T-cells that
produced IFN-g and TNF to levels comparable to the positive control viral peptide (Figure 3.28)
while the same cultures pulsed with CITF D459G negative control peptide showed low cytokine
response. These data indicate that the analysis pipeline described, successfully identified tumor
specific antigens that could be used to vaccinate a FL patient and yield detectable antigen specific
T cells with potent effector functions.

Figure 3.28: Successful identification of tumor specific antigens.
Antigen specific CTLs from D12 cultures were challenged with artificial antigen presenting cells pulsed
with specific peptides, incubated for six hours and then IFN-g or TNF expressing CD3/CD8 DP cells
were detected by Fluorescence-Activated Cell Sorting (FACS).
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3.4 Discussion
In this study a retrospective comprehensive exome and transcriptome profiling to define
the neoantigen landscape and assess feasibility of neoantigen vaccine approaches in 58 FL cases
was completed. We performed HLA typing, mutation calling, BCR clonotyping, fusion calling,
neoantigen prediction, checked for presence of mutations in antigen presenting machinery and
performed in silico vaccine design from comprehensive whole exome and transcriptome sequence
data for each patient. Low TMB should not necessarily preclude patients from consideration for a
personalized vaccine strategy as the optimal number of neoantigens needed for a successful
vaccine is unknown. At least one peptide (mean: 16, range: 0-38) suitable for cancer vaccine
generation was identified for all but two patients (97%) and 95% patients had more than one
vaccine candidate. These predicted high quality neoantigens include those which arose from genes
known to be recurrently mutated in FL as well as from presumed passenger mutations. This
suggests that key known FL driver genes may play an important role in neoantigen vaccine design.
Additionally, we incorporated follicular lymphoma biology by creating an integrated BCR analysis
pipeline to identify high quality neoantigen vaccine candidates within the CDR3 region of the
BCR. This preclinical proof-of-principle research was then translated into a pilot clinical trial of
neoantigen vaccination in FL patients and patient T cell responses were assessed.
Previous tumor vaccine strategies targeted B-cells specifically using antibodies against
their unique surface immunoglobulins in an attempt to circumvent FL’s heterogeneous mutational
landscape. However, these approaches only contained a single cancer target, patients received
cytotoxic chemotherapy in the interim, and it recently failed to meet primary endpoints within a
Phase III clinical trial (Freedman et al., 2009; Levy et al., 2014; Schuster et al., 2011). Emerging
evidence now emphasizes that immune elimination of a tumor requires immune targeting of
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multiple neoantigens. This could explain why targeting a single antigen receptor on B-cell
lymphomas led to the evolution of antigen loss variants of the parental tumor (Yarchoan et al.,
2017). Recent studies have shown a trend towards increasing numbers of neoantigens being
incorporated into patient tumor vaccines (Carreno et al., 2015; Keskin et al., 2019; Ott et al., 2017;
Ugur Sahin et al., 2017). These multi-target personalized neoantigen cancer vaccines may broaden
and enhance anti-tumor immune response and improve clinical efficacy within FL patients, as has
been shown in late-stage melanoma patients (Hellmann & Snyder, 2017).
Vaccine design in this study was informed by the unique mutational landscape of FL.
Recurrently mutated genes were consistent with previous reports (Correia et al., 2015; Green et
al., 2013; Krysiak et al., 2017; Okosun et al., 2014; Pasqualucci et al., 2014) and a number of novel
potential driver fusion events were also identified. In total, 67% of our cohort contains at least one
predicted high quality neoantigen vaccine candidate within a recurrently mutated gene identified
within the genomic landscape of FL. For example, 25% of our cohort contained at least one
KMT2D predicted high quality neoantigen vaccine candidate and all but two of the candidates
resulted from frameshift mutations. Disruption of KMT2D/MLL2 has been found to promote
lymphomagenesis in the context of BCL2 overexpression and identified as a putative premalignant precursor, and rationale target for eradication (Ortega-Molina et al., 2015; Zhang et al.,
2015). Thus KMT2D/MML2 variants may represent promising cancer vaccine candidates to target
within a substantial fraction of FL patients. Furthermore, 20% of our cohort contained at least one
BCL2 predicted high quality neoantigen vaccine candidate and all candidates resulted from
missense mutations. Additionally, 40% (23/57) of the cohort harbored unique fusion genes (Figure
3.3). The most recurrently identified fusion gene pair was a frameshift ARL17A--KANSL1 found
within 4 patients. ARL17A--KANSL1 has been reported as a recurrent event in T-cell
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lymphoblastic lymphoma, glioblastoma multiforme, multiple cancer cell lines and normal tissues,
but not in FL (López-Nieva et al., 2019; Mehani et al., 2020; J. X. Zhou et al., 2017). ARL17A
encodes a tumour suppressor gene protein of the ARF family that is involved in pathways related
to human carcinogenesis (Yendamuri et al., 2008). While the partner KANSL1 encodes a nuclear
protein that is a subunit of two protein complexes (the MLL complex and NSL1 complex) involved
in histone acetylation. The absence of KANSL1 and ARL17A functional domains could
potentially result in reduced activities in histone acetylation, control of chromosome segregation,
cell division and replication. BCL6 was also involved in fusions with different gene partners
occurring within 4 patients. Genes such as CREBBP, POU2F2, CD74, IRF4, and KLF2 known to
be involved in FL, were also identified as gene fusion pairs within our patient cohort. A total of
25 gene fusions (mean: 2, range: 0-4) were predicted to be high quality neoantigen vaccine
candidates within 25% (14/57) of the entire cohort (Figure 3.11). Overall somatic point mutations
and fusions in known FL driver genes contributed significantly to vaccine design.
While recurrently mutated (known driver) genes featured regularly in vaccine design,
recurrent mutations across different patients (i.e., hotspots) did not. As a result, personalized
vaccine designs will likely be needed for FL. From the 783 predicted high quality neoantigens
resulting from small somatic mutations, only 6 specific variants are shared between 2 patients and
1 variant shared between 3 patients. Furthermore, even a shared variant does not necessarily predict
that patients will share a neoantigen because of differences in HLA alleles. For example, of the 6
variants shared between two patients, only 3 resulted in the same predicted high quality neoantigen
when accounting for patient HLA alleles. Similarly, the BCL2 variant R129H shared by 3 different
patients (LYM783, LYM235, and LYM730) all resulted in different neoantigen candidates
(TPFTARG-H-F, FTARG-H-FATV, and H-FATVVEEL) due to their specific HLA alleles.
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Together, these observations suggest that custom or patient-specific vaccines will improve patient
outcomes in relation to a one size fits all approach.
It may also be important for a personalized cancer vaccine to target both clonal and
subclonal tumor populations. Tumors are heterogeneous, have the potential to evolve and create
subclones, spatially and temporally separated (de Bruin et al., 2014; Gejman et al., 2018; Gerlinger
et al., 2012; McGranahan et al., 2016; Milo et al., 2018). We now have the ability to infer tumor
clonal ancestry through the identification of somatic mutations with genome sequence data and
assess whether these mutations are actively transcribed with transcriptome sequence data. This
could allow targeting neoantigens that are both clonal and subclonal, producing an anti-tumor T
cell response that can help eliminate the entire tumor population. The average tumor DNA VAF
for predicted high quality neoantigens within our cohort was 26.3%, ranging from 5.0% to 97.7%
and most patients (81%) had evidence of subclonal architecture. For example, patient LYM1376
had the most predicted high quality neoantigens (36/153 small somatic mutations), and these
neoantigens represented both clonal and subclonal populations. We identified an average of 7
(range: 1-13) predicted high quality neoantigen targets from each of the five predicted clonal and
subclonal populations within LYM1376 (Figure 3.21). This result illustrates that we were able to
not only identify subclonal somatic mutations, but also successfully predict high quality
neoantigens that encompass the entire tumor population. Successful vaccine design may need to
consider subclonal architecture in FL and would benefit from additional studies that take advantage
of high-depth targeted validation sequence and multi-sector sequencing (Wassermann et al., 1988).
Encouragingly, our retrospective analysis suggests that nearly all FL patients may be
candidates for clinical trials that incorporate multiplexed personalized cancer vaccines. Recent
studies support multiplexed neoantigen cancer vaccines combined with anti-PD-1 monoclonal
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antibody (mAb) because it is able to remove tumor mediated immunosuppression and stimulate
neoantigen-specific T cells that were generated by the vaccine (Ott et al., 2017; Ugur Sahin et al.,
2017). These pre-clinical results led to our first-in-human personalized neoantigen vaccine trial,
using up to 20 neoantigens in the form of synthetic long peptides, based on mutational profiling
and RNA expression analysis of surgically resected tumors combined with anti-PD-1 mAb in
patients with rel/ref FL (NCT03121677). Preliminary results are encouraging with no serious
adverse events and with one CR observed within 3 patients evaluable for response to date. Pilot
clinical trials such as these are the ultimate test of our bioinformatic predictions as they will provide
clinical response data and immunological correlates which we can then use to improve our
neoantigen prediction pipelines. This study supports ongoing early phase clinical trial assessment
of neoantigen vaccines in lymphoma, which generally match the goals of a chemotherapy-free
immunotherapy without major short and long-term adverse events.
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3.5 Methods
3.5.1 Patient characteristics and sample acquisition
Four sets of patient samples were included. Sets 1-3 (54 patients, 306 total samples) were
retrospectively collected cases from our lymphoma bank (sample IDs beginning with LYM). All
patients provided written informed consent for the use of their samples in sequencing as part of
the Washington University School of Medicine (WUSM) Lymphoma Banking Program.
Excisional biopsy tissue and nonmalignant (skin punch biopsies) samples were collected (20082019). Pathology review was performed on frozen lymph node samples to confirm the diagnosis
and estimate tumor cell content. Frozen sections (tumor and skin) were cut and used for genomic
DNA isolation. Flow sorting was performed on a Reflection instrument. LYM520 RNA-Seq
material was excluded due to RNA degradation, this was the only patient without RNA-Seq data.
Set 4 (4 patients, 21 total samples) were prospectively collected for a pilot immunotherapy trial
(Sample IDs beginning with FLNA). Tumors and uninvolved skin biopsies were obtained, and
flash frozen from consented (NCT03121677) individuals at Barnes-Jewish Hospital and reviewed
to confirm the pathology diagnosis. All samples were collected within protocols approved by the
WUSM institutional review board (201108251, 201804151) and all clinical characteristics are
summarized in Table 3.1. PBMCs were obtained from four months post vaccination apheresis.
The cells were isolated by standard Ficoll-paque Plus gradients and viably cryopreserved for later
analysis.
FLNA-04, patient vignette: A sixty-nine-year-old female with multiple cervical and
supraclavicular LN PET positive involvement. Eight years prior to entry into this study, the patient
was treated with R-CHOP and experienced a three-month CR. She later showed progressive
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disease and began Rituxan/Bendamustine with Rituxan maintenance for two years. Upon relapse,
the patient underwent an excisional biopsy used for DNA and RNA isolation and sequencing using
uninvolved skin as a control. The patient completed all doses as prescribed by clinical trial
(#NCT03121677) and experienced a CR at two months post treatment. The patient is off study
and remains disease free by PET/CT scans.

3.5.2 Library preparation and sequencing
Set 1: Genomic DNA was isolated using the QIAamp DNA Mini kit, with xylene.
Library preparation, capture hybridization, and sequencing were performed as previously
described.27 Briefly, DNA fragmentation was performed using the Covaris LE220 targeting an
average fragment size of 200 bp. Dual indexed libraries were prepared using the KAPA HTP
library prep kit (KAPA Biosystems) on the SciClone NGS instrument (Perkin Elmer). The final
libraries were assessed using the LabChipGX (Perkin Elmer). Exome library capture was
performed using the NimbleGen SeqCap EZ Exome v2.0 reagent. Sequencing was performed on
a HiSeq 2000 with 2x100bp reads. Sequencing data have been deposited (dbGaP accession:
phs001229).
Set 2: Genomic DNA was isolated using the QIAamp DNA mini kit. RNA was extracted
using the Qiagen RNeasy extraction kit. DNA fragmentation was performed using Covaris LE220
targeting an average fragment size of 200 bp. Dual indexed libraries were prepared using TruSeq
PCR-free (for WGS), and KAPA HTP (for WES), and TruSeq Stranded Total RNA (for RNA).
DNA libraries were pooled and captured using the NimbleGen SeqCap EZ Exome v2.0 reagent or
IDT exome kit. Sequencing was performed on a HiSeqX with 2x150bp reads for WGS, HiSeq
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2500 with 2x125bp for RNA, and HiSeq 4000 with 2x150bp for WES. Sequencing data have been
deposited (dbGaP accession: phs001229).
Set 3: For cases that were flow sorted, CD19+ and light chain restricted B cells were
purified (>98% pure) using a Reflection instrument. Genomic DNA was isolated using the
QIAamp DNA mini kit. RNA was extracted using the Qiagen RNeasy extraction kit. DNA
fragmentation was performed using Covaris LE220 targeting an average fragment size of 200 bp.
Dual indexed libraries were constructed for DNA using the KAPA Hyper (Amplified) library prep
kit on the SciClone NGS instrument. RNA libraries were constructed using Illumina TruSeq
Stranded Total RNA Library Prep Gold. Corresponding (DNA and RNA) libraries were pooled
and captured using an IDT exome kit. The final libraries were assessed using the LabChipGX.
Sequencing was performed on Illumina HiSeq 4000 with 2x150bp reads. 15 normal samples were
pooled/captured on 1 lane and 15 tumor samples were pooled/captured on 2 lanes for exomes. A
total of 4 pools (5 libraries per pool) were captured on a total of 4 lanes (1 lane per pool) for RNASeq. Sequencing data have been deposited (dbGaP accession: phs001229).
Set 4: Genomic DNA was isolated using the QIAamp DNA mini kit. RNA was extracted
using the Qiagen RNeasy extraction kit. DNA and RNA were fragmented using the Covaris LE220
targeting an average fragment size of 200 bp. Dual indexed libraries were constructed for DNA
using the Kapa Hyper (Amplified) library prep kit. RNA libraries were constructed using Illumina
TruSeq Stranded Total RNA Library Prep Gold. The concentration of each library was determined
through qPCR utilizing the KAPA library Quantification Kit. Corresponding (DNA and RNA)
libraries were pooled and captured using an IDT Exome Capture Hybridization exome kit. DNA
libraries were captured in one pool at a ratio of 60% tumor to 40% normal and sequenced on a
NovaSeq6000 with 0.017 S4 flow cells with 2x150 bp reads. RNA libraries were captured
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separately and sequenced on a NovaSeq6000 with 0.010 S4 flow cell with 2x150 bp reads.
Sequencing data have been deposited (dbGaP accession: phs001229).

3.5.3 Parallel pipeline analysis:
Two separate parallel analyses were conducted (referred to as WashU analysis pipeline and
BostonGene analysis pipeline in subsequent text) with the same starting material of raw
sequencing data (WGS, WES and RNA-Seq). The WashU analysis pipeline was used for the
following analyses: 1) Mutational landscape depicted in Fig 3.2; 2) Identification of fusion genes
described in Fig 3.3; 3) BCR clonality analysis depicted in Fig 3.6, 3.14; Table 3.2, 3.3; 4)
Neoantigen vaccine candidates discussed in Fig 3.8-3.13; 5) Clonality analysis Fig 3.19-3.21.
The BostonGene analysis pipeline was used for the following analyses: 1) BCR clonality
analysis depicted in Fig 3.4, 3.5, 3.7; Table 3.4; 2) Neoantigen vaccine candidates discussed in
Fig 3.15; Table 3.5; 3) Analysis of the MHC machinery and immune activity signature analysis
described in Fig 3.16-3.18. Both pipelines were used to arrive at a final vaccine candidate list for
the 4 patients enrolled in the pilot trial described in Fig 3.24-3.28; Table 3.16.

3.5.4 Retrospective neoantigen analysis:
Sequence alignment and SNV/Indel variant calling
For sequencing data Sets 1-3 the WashU analysis pipeline first performed all alignments
using the Genome Modeling System. Briefly, for exome data, paired-end reads were aligned to
human reference sequence GRCh37, using BWA-MEM (v0.7.10), and de-duplicated using Picard
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(v1.8.5). Variants were identified using SAMtools (v0.1.18), SomaticSniper (v1.0.4), VarScan2
(v2.3.6), MuTect (v1.1.4), Strelka (v1.0.11), Pindel (v0.2.0), Breakdancer (v1.4.5) and GATK
(v2.4.0), and annotated using the Variant Effect Predictor (VEP) (release 93.2) software for
annotation of protein-coding effect of variants. Variants were filtered to remove common variants
and pipeline artifacts. Manual review was performed as previously described. For RNA-seq data,
FastQC (v0.10.0) and SAMStat (v1.0.8) were used to assess quality. Then the data was aligned to
human reference sequence GRCh37 using Bowtie (v2.1.0) and TopHat (v2.0.8). Cufflinks (v2.1.1)
was used to assemble transcripts, estimate their abundance and test for differential expression and
regulation. BEDtools (v2.14.3) was then used to calculate read depth and create coverage plots.
For sequencing data Set 4 the WashU analysis pipeline first performed paired end read
alignment to human reference sequence GRCh38, using BWA (v0.7.15), and de-duplicated using
Picard (v2.18.1) and SAMBLASTER (v0.1.24). Variants were identified using SAMtools (v1.3.1),
VarScan2 (v2.4.2), Strelka (v2.9.9), Pindel (v0.2.5) and GATK (v3.6.0) and annotated using the
Variant Effect Predictor (VEP) (release 93.2) software for annotation of protein-coding effect of
variants. Variants were filtered to remove common variants and pipeline artifacts. Manual review
was performed as previously described. For RNA-seq data, Picard, FastQC (v0.11.8) and Samtools
(v1.3.1) were used to assess quality. Then the data was aligned to human reference sequence
GRCh38 using HISAT2 (v2.0.5). StringTie (v1.3.3) and Kallisto (v0.43.1) were used to assemble
transcripts (StringTie) and estimate their abundance.
The BostonGene analysis pipeline first aligned all exome data to the human reference
genome GRCh38 (GRCh38.d1.vd1) using BWA v0.7.17. Duplicate reads were marked by Picard’s
v2.6.0 MarkDuplicates, indels were realigned and base quality was recalibrated by GATK v3.8.1.

117

Somatic single nucleotide variations (sSNVs), small insertions and deletions were identified using
Strelka v2.9.

Identification of candidate fusion transcripts
For sequencing data Set 1-3 the WashU analysis pipeline first aligned quality filtered reads
using STAR-Fusion (v1.7.0) against transcriptome (GRCh37 Genecode v19 CTAT lib
annotations) and genome (GRCh37) to identify fusion transcripts. Fusions were then filtered based
on the following criteria: 1) Supported by at least 5 total reads (Junction plus Spanning reads), 2)
Does not contain a pseudogene as a fusion gene partner, 3) Gene pairs were at least 1 Megabase
apart. The remaining fusion candidates were then realigned using FusionInspector (v1.9.1) and
alignment data was manually reviewed using Integrative Genomics Viewer (v2.7.0).
For sequencing data Set 4 the WashU analysis pipeline first aligned quality filtered reads
using STAR-Fusion (v1.7.0) against transcriptome (GRCh38 Genecode v36 CTAT lib
annotations) and genome (GRCh38) to identify fusion transcripts. Fusions were then filtered based
on the following criteria: 1) Supported by at least 5 total reads (Junction plus Spanning reads), 2)
Does not contain a pseudogene as a fusion gene partner, 3) Gene pairs were at least 1 Megabase
apart. The remaining fusion candidates were then realigned using FusionInspector (v1.9.1) and
alignment data was manually reviewed using Integrative Genomics Viewer (v2.7.0).
The BostonGene analysis pipeline detected gene fusions utilizing STAR-fusion v1.8.1.
RNA-Seq data was aligned to the same genome by STAR v2.4.2 followed by realignment and base
quality recalibration.
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B-cell receptor alignment and analysis:
The WashU analysis pipeline consisted of the following steps: To determine a patient's Bcell receptor repertoire patient RNA-Seq data (fastq) was analysed with MiXCR (v3.0.2) with the
following parameters: analyze shotgun -s HomoSapiens --starting-material rna --receptor-type
bcr --contig-assembly. First, for all MiXCR clonotype results (files ending with
“.clonotypes.IGH.txt “), including the aaSeqFR3, aaSeqCDR3 and aaSeqFR4 amino acid
sequences were concatenated. Next, the counts for these concatenated amino acid sequences were
collapsed if identical or entirely contained within a longer sequence, and total clone count summed.
All immunoglobulin heavy (IgH) chain and immunoglobulin light/kappa (IgL/K) chain clonotypes
were then separated into two groups and their corresponding clone count was then used to
recalculate their respective clone fraction. Clonotypes with clone fractions greater than or equal to
9% were labeled as clonal B-cells.
The BostonGene analysis pipeline consisted of the following steps: BCR profiling was
conducted using MiXCR v3.0.12 from RNA-Seq reads using default options for shotgun
sequencing. To capture somatic hypermutations in malignant B-cells all the related BCR
clonotypes sharing the same V(D)J segments and CDR3 regions differing by no more than two
nucleotides were combined into clonotype groups. Normal BCR structures were obtained from
publicly available bulk RNA-Seq samples with high B cell population according to the tissue of
origin, in total 110 samples. BCR profiling was performed as described above. Only high covered
samples with more than 100 assembled clonotypes in each of the chains (heavy, kappa and lambda)
were kept for further analysis. Publicly available datasets used: GTEx phs000424
(N=15)(Lonsdale et al., 2013), GSE90081 (N=12)(Shchetynsky et al., 2017), GSE112057
(N=12)(Mo et al., 2018), GSE61410 (N=4)(Dvinge & Bradley, 2015), GSE111405 (N=3)(Chen

119

et al., 2018), GSE63816 (N=3)(Madan et al., 2015), GSE58335 (N=2)(Dvinge et al., 2014),
GSE43603 (N=1)(Visconte et al., 2012), GSE57944 (N=1)(Ferreiro et al., 2014).

Vaccine candidate prioritization and analysis
The WashU analysis pipeline consisted of the following steps: To determine a patient’s
HLA class I allele type we used OptiType (v1.3.3) on normal WES data. Epitope predictions were
performed for each patient’s mutation(s) against all 6 of their predicted HLA class I alleles using
pVACtools (v1.5.3). All patient-predicted peptides were condensed to the single best high-quality
candidate based on binding affinity. Small somatic variant neoantigen candidates (pVACtools
pVACseq results) were further filtered using the following criteria: (1) HLA binding affinity IC50
≤ 500 nmol/L; (2) normal/tumor DNA/RNA coverage > 10; (3) normal DNA variant allele
frequency (VAF) < 1%; (4) tumor DNA/RNA VAF > 5%; and (5) gene/transcript expression
FPKM > 0. B-cell clonotype neoantigen candidates (pVACtools pVACbind results) were filtered
to identify HQC using the following criteria: (1) B-cell clonotype percentage ≥ 9% and (2) HLA
binding affinity IC50 ≤ 1,000 nmol/L. Gene fusion neoantigen candidates (pVACtools pVACfuse
results) were filtered to identify HQC using the following criteria: (1) A minimum of 5 total
junction and/or spanning reads and (2) HLA binding affinity IC50 ≤ 500 nmol/L.
The BostonGene Vaccine Module V1 reconstructs candidate tumor specific peptides by
assembling mutant transcripts from tumor RNA reads. Mutant transcripts are identified as those
supporting somatic variants previously evaluated from exome data. The Module uses IsoVar v0.7.0
to reconstruct such peptides. HLA genotypes were identified from RNA-Seq data using seq2hla
v2.2. Peptide-HLA affinity is evaluated by a custom prediction model. Briefly an allele-specific
gradient boosting model was trained on curated data from IEDB and validated on independent
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datasets. Peptide encoding scheme included 1-hot encoding and peptide features such as mass,
isoelectric point, hydrophobicity, instability index according to Guruprasad et al, 1990 and
flexibility according to Vihinen, 1994. Fusion derived neoantigens were predicted by
INTEGRATE-Neo (v1.2.1) from the events identified by STAR-fusion (v1.8.1) using NetMHC
4.0 for neoantigen-HLA affinity evaluations. Fusions should have been supported by at least 10
junction reads and neoantigens-HLA IC50 should be under 500nM.

Evaluating efficiency of antigen presenting machinery:
To evaluate antigen presenting machinery (APM) status in FL cells we analyzed expression
levels of HLA class I & II genes and somatic aberrations in genes involved in APM function. To
correctly evaluate polymorphic HLA genes expression, we replaced HLA transcripts in
GENCODE 33 assembly with IMGT set of HLA transcripts and used kallisto to quantify
transcripts abundance for the samples. Then we normalized expression by log-transform followed
by median-transform scaling within each of the batches (Figure 6c). Then we identified nonsynonymous mutations and gene fusions in these samples (Figure 6b) for 32 manually selected
genes known to be involved in APM. Gene fusions were calculated by STAR-fusion, small
variants - by Strelka (see Sequencing alignment and variant calling above for details).

Molecular functional profiling
We evaluated activity of key tumor microenvironment components and processes using a
curated set of gene expression signatures (Cerchietti et al., 2019). Briefly for each selected
cellular or functional component a gene set was constructed and optimized by comprehensive
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review and inhouse analysis of subject related publications and data. Each signature is evaluated
using ssGSEA algorithm and normalized by median transformation within the corresponding
RNA-Seq batch. Finally, hierarchical clustering was performed on this data by complete linkage
and Euclidean distance.

Evaluating clonal and subclonal architecture of FL samples
We used SciClone (v1.0.7) for single region subclonal reconstruction. Input VCFs were
used to calculate variant allele frequencies and CNA inputs were used to determine regions with
loss of heterozygosity. Only SNVs in clonally copy number neutral (major = 1, minor = 1) regions
with no subclonal CNAs were considered by SciClone (v1.0.7) and all samples were run using
default parameters. Mutation clusters defined by SciClone (v1.0.7) were characterized using
variant allele frequencies.

3.5.5 Pilot trial neoantigen analysis
Sequencing alignment and SNV/Indel variant calling:
The same analysis strategy was used as described above for the retrospective neoantigen
analysis.
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B-cell receptor alignment and analysis:
The same analysis strategy was used as described above for the retrospective neoantigen
analysis, with one exception: Clonotypes with clone fractions greater than or equal to 9% were
labeled as clonal B-cells; however, if no clonal B-cell populations could be identified than the
largest IgH and IgL/K clonotypes were labeled as the patient’s clonal B-cells.

Vaccine candidate prioritization and analysis:
The WashU analysis pipeline consisted of the following steps: To determine a patient’s
HLA class I allele typing we used OptiType (v1.3.3) on normal WES data. Epitope predictions
were performed for each patient’s mutation(s) against all 6 of their predicted HLA class I alleles
using pVACtools (v1.5.3). All patient-predicted peptides were condensed to the single best highquality candidate (HQC) based on binding affinity. Small somatic variant neoantigen candidates
(pVACtools pVACseq results) were further filtered using the following criteria: (1) HLA binding
affinity IC50 ≤ 500 nmol/L; (2) normal/tumor DNA/RNA coverage > 10; (3) normal DNA
variant allele frequency (VAF) < 10%; (4) tumor DNA/RNA VAF > 5%; and (5) gene/transcript
expression FPKM ≥ 1. However, to achieve the maximum number of vaccine candidates (20)
possible per patient, the previous filtering criteria were relaxed in reverse order creating 6 tiers.
Tier1 candidates passed all filtering criteria. Tier2 candidates ignored filtering criteria 5 only.
Tier3 candidates ignored filtering criteria 4 only. Tier4 candidates ignored filtering criteria 3
only. Tier5 candidates ignored filtering criteria 2 only. Tier6 candidates ignored filtering criteria
1 only. The same BostonGene Vaccine Module V1 strategy used within retrospective neoantigen
analysis was also applied to trial patient data. The union of both methods (WashU and
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BostonGene analysis pipelines) were used together to ensure that no potentially important
candidates were missed due to differences of analysis. If a candidate was identified by the
BostonGene analysis pipeline and not by the WashU analysis pipeline, then an investigation was
conducted to evaluate the missing candidate and determine if it should be included within the
patient’s vaccine. The largest IgH and IgL/K B-cell clonotype population’s CDR3 regions were
considered high quality neoantigen vaccine candidates.

Vaccine candidate design, pooling strategy and manufacturing
All short and BCR peptide vaccine candidates were BLASTp aligned against the human
reference genome to ensure that the neoantigen vaccine candidate did not match any other
portion of the human genome, to avoid off target-effects. Next, all somatic short peptides (8-11
amino acids) were required to have a long peptide (25 amino acids) register, with preservation of
the short peptide after proteasome processing by NetChop. Additionally, inclusion of multiple
long peptide registers was selected for a given somatic short peptide when possible. All BCR
long peptide (25 amino acids) registers were selected by subtracting the BCR CDR3 vaccine
candidate amino acid lengths from the total and then including the difference of amino acids
given the flanking FR3 and FR4 corresponding to a left (inclusion of FR3 flanking amino acids
only), middle (equal inclusion of FR3 and FR4 amino acids) and right (inclusion of FR4 flanking
amino acids only). Long peptide N- and C-terminus sequence recommendations (generally, do
not start or end with a bulky amino acid): avoid Glutamine (Q) at the N-terminals and avoid
Cysteine (C) and Proline (P) at the C-terminals. Additionally, all long peptide vaccine candidates
were BLASTp aligned against the human reference genome to ensure that the neoantigen
vaccine candidate did not match any other portion of the human genome to avoid off target124

effects. GMP grade vaccinating peptides synthesized by CreoSalus using standard solid-phase
synthetic chemistry and then purified using reverse phase-HPLC. Up to twenty long peptides
were combined into four pools, minimizing competition for MHC, taking into consideration
predicted binding affinities, for limb specific injection. Immediately before inoculation, pools
were emulsified with Hiltonol (Poly-ICLC), Oncovir, Inc by the Siteman Cancer Center Clinical
Pharmacy.

Clinical trial design and approval:
To assess the feasibility and safety of a personalized neoepitope SLP vaccine in
combination with nivolumab we initiated a pilot trial (IRB and FDA IND-approved, open to
accrual, NCT03121677, Figure 3.22-3.23). Vaccine was administered in combination with
polyIC:LC (Hiltonol), a TLR3 agonist immune adjuvant, and nivolumab (anti PD-1), in four, limb
specific pools (described above) at the study designated time points. Patients who progress on
post-cycle 2 or post-cycle 6 restaging were allowed to receive rituximab in combination with
vaccine and nivolumab in an effort to keep patients safely on trial and still meet the critical
correlative time points. A detailed chronological treatment schema is shown in Figure 3.22.
Eligible patients must have had relapsed FL which had been previously treated with an anti-CD20
antibody and an alkylator. Patients were ineligible if they were refractory to rituximab, required
therapy within the last 6 months, had a history of transformed follicular lymphoma, or had prior
therapy with PD-1 inhibitors. Patients were required to have a tumor accessible for biopsy and
were deemed to be appropriate for initiation of the next line of therapy for 4 to 5 months. Primary
outcome measures of the trial are feasibility and safety of the neoantigen vaccine in combination
with nivolumab as measured by the number of participants whose personal vaccines can be
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manufactured and delivered without unacceptable toxicity. Unacceptable toxicity is defined as the
inability to receive further therapy due to toxicities of therapy as defined by NCI Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03 or the occurrence of other
toxicities deemed to be at sufficiently high risk to patients by the principal investigator. Secondary
outcome measures include overall response rate (ORR), complete response (CR) rate, duration of
response, progression-free survival (PFS), overall survival (OS), and partial response (PR) rate.

Identification of candidate encoding peptides binding to HLA A*68:01
A tap deficient cell line was created by expression of ICP-47 (gift from Ted Hansen)
under puromycin selection in the Class I negative, lymphoblastoid cell line, 721.221 (gift from
M. Colonna, Washington University Saint Louis). A TAP negative clone was transduced with
synthetically constructed, HLA A*68:01 in a IRES GFP retrovirus. The greater than 95% GFP
positive cell line was serum starved for 1 hour prior to plating with various concentrations of in
silico predicted candidate short peptides synthesized by GenScript to greater than 90% purity.
Peptides corresponding to candidate nonomers were solubilized in 10%DMSO and then
incubated with the Class I specific/TAP deficient cell line for three hours at ambient temperature
in RPMI1640 containing 100 mM HEPES, 2mM glutamine, 1000 un/mL Penicillin/, 1mg/mL
Streptomycin, and 1% (v/v) heat inactivated human AB serum. The cells were shifted to 37C for
overnight incubation then washed twice and stained with fluorescently labeled W6/32
monoclonal antibody to detect Class I expression. Cells were washed twice and then collected
on a Beckman Coulter Navios flow cytometer utilizing 7-AAD viability dye to exclude dead
cells from later cell analysis. Flow cytometric data was analyzed on FlowJo v. 10.6.1. Mean
fluorescence intensity (MFI) of 7-AAD negative/GFP positive/W6/32 positive cells was
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determined in duplicate for each peptide concentration. Figure 6C, shows the MFI over baseline
(cells with no peptide) for the candidates that stabilized peptides relative to the FluNP 91-99
positive control and CITF D459G negative control peptide. The red line shows baseline W6/32
MFI of the highest concentration of CITF D459G negative control peptide. The results shown
are the average of three independent determinations.

ELISPOT
Two million PBMCs from four-month post vaccination were stimulated with vaccine
long peptides (LP) at 40 ug/mL in complete OpTmizer T-cell media (Gibco) supplemented with
5% human AB serum. Cells were fed every other day with 50 um/mL IL-2 (Proleukin) until day
ten and then used in a standard IFN- ELISPOT assay (Cellular Technologies Limited, OH) using
the predicted minimal short peptide candidates for re-stimulation. Developed plates were
counted and analyzed blindly by the Immunomonitoring lab at the Bursky Center for Human
Immunology and Immunotherapy Center, Washington University) on a C.T.L.-Immunospot S6
Universal Analyzer. Results were de-convoluted and shown in Figure 6E as spots per 1e6
PBMC.

Tetramer Assay
Day ten stimulated PBMCs used in the ELISPOT were stained with freshly prepared
HLA A*68:01 tetramers containing the minimal short peptide (SP) candidates fluorescently
labeled with PE and APC for 30 min at ambient temperature. Additionally, 7-AAD-/CD19-
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/CD56-/CD3+/CD8+ T cells double positive for tetramer PE and tetramer APC were considered
antigen specific T cells.

Intracellular Cytokine Assay
Class I negative K562 leukemic cells were transduced with HLA A*68:01 with GFP and
sorted to >95% purity and used as an artificial antigen presenting cell (AAPC). AAPC were
loaded with short peptide of interest for one hour, washed, irradiated and then mixed at a 5:1
(E:T) ratio with day ten LP stimulated PBMCs. Cells were treated with BrefeldinA and
monensin and intracellular cytokine was allowed to accumulate for six hours. Cells were then
stained for IFN- and TNF as previously described.(Romee et al., 2016) After six hours, cells
were stained with Zombie green (ZG) (Biolegend) to remove dead cells from the analysis and
CD45+/CD3+/CD8+ cells were examined for expression of the inflammatory cytokines IFN-g
and TNF. Data was collected on a BeckmanCoulter Navios Flow Cytometer and analyzed on
FlowJo (v10.6.1).
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Chapter 4: Conclusions and future directions
In this work we: (1) Showed that large multi-center sequencing studies are extremely
prone to sample duplicates, misidentification and clinical meta-data errors. Extensive clinical and
genetic data review are necessary. (2) Confirmed key genes and pathways driving FL and
identified novel FL SMGs involved in BCR/CXCR4 signaling, SWI/SNF complex and histone
genes. (3) Demonstrated feasibility of personalized neoantigen vaccine design despite modest
overall mutation burden in FL. (4) Determined that a comprehensive approach considering
multiple sources of neoantigens including SNVs, Indels, fusions and BCR rearrangements is
necessary to maximize potential success of a neoantigen vaccine. (5) Initiated a pilot clinical trial
of neoantigen vaccine and checkpoint blockade with 4 patients enrolled to date, demonstrating
safety and promising clinical and immunologic responses in FL.
Great strides have been made in the comprehensive characterization of the genomic and
neoantigen landscape of FL patients, but there is still significant room for improvement. The
research described above should help to lay the groundwork to (1) identify prognostic
biomarkers capable of identifying high-risk patients at diagnosis, (2) help identify predictive
biomarkers that targeted agents should be designed for, (3) help determine personalized
treatment plans for patients based on their genomic profiles from trends observed in our research,
(4) help to identify and prioritize neoantigens within lymphoma patients quickly and (5) increase
the utilization of personalized cancer vaccines within clinical trials for lymphoma patients.
Achievement of these goals would facilitate a personalized approach to the management of FL.
We believe our research represents a significant advance in the efforts to characterize the
genomic landscape of FL. However, several limitations and future work remain to be addressed
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in order to completely characterize the genomic landscape of FL. Our study at maximum
encompasses 9% (1,716 genes) of the total predicted human protein-coding genome within 515
samples from 370 unique patients making it the largest cohort with the most genes sequenced to
date. It further expanded to 13% (2,697 genes) coverage for 174 samples from 125 unique
patients within the same cohort. Our custom capture panels are extremely powerful as they allow
us to focus on previously described genes, networks and/or pathways that were determined to be
of importance while making it more affordable to sequence, with sufficient coverage, more
samples for increased statistical power. However, they are clearly limited in the fact that 87-91%
of the human protein-coding genome was not sequenced within this study for various samples.
Additionally, we know that alterations in protein-coding genes are not the only factors
influencing a patient’s cancer and numerous other genetic and epigenetic factors should be
studied and taken into account, including changes in methylation state, chromatin state, noncoding alterations, large-scale changes, and more (Hanahan & Weinberg, 2011; Sharma et al.,
2010). Therefore, as research within the field moves forward, we believe that all patients
diagnosed with FL should receive tumor-normal paired whole genome, transcriptome, and
epigenome profiling. This would allow for the slow accumulation of high quality genome-wide
data for researchers to study, leading to the completion of the FL genomic landscape and
increased use of personalized cancer treatments. Finally, finding an effective way to share our
data among research oncologists worldwide would significantly advance our collective
knowledge and ability to conduct research necessary to advance the field of precision medicine.
Several limitations and future work also remain to be addressed in order to improve the
accuracy and effectiveness of personalized cancer vaccines for FL. It is currently unclear what
factors may contribute to the ultimate success or failure of personalized cancer vaccines (Richters
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et al., 2019; Wells et al., 2020) and clinical trial results published to date show a low accuracy for
neoantigen prediction pipelines (Linette & Carreno, 2017). Additionally, poor concordance was
observed between 25 teams that independently predicted and ranked neoantigens using a common
data set (Wells et al., 2020). Factors that could influence a patient’s personalized cancer vaccine
include but are not limited to: 1) neoantigen identification pipelines, 2) HLA typing predictions,
expression, and mutations, 3) peptide processing prediction, 4) MHC binding predictions, 5)
vaccine design/delivery approach including neoantigen vaccine form (synthetic peptides, DNA
vector, etc.), 6) T-cell recognition, and 7) tumor immune microenvironment. Tools currently
available to predict or evaluate these factors are imperfect, require further optimization, or have
yet to be incorporated into our pipeline. For example, the specific T-cell receptors that recognize
epitopes bound to MHC need to be further analyzed with the hope of modeling epitope-TCR
specificity (Dash et al., 2017). Recently, multiple tools (such as TCRex, NetTCR, Repitope) have
been released to address this specific interaction when provided with TCR sequences. This
additional information could help to further prioritize neoantigen vaccine candidates based on their
predicted immunogenicity.
The cancer research effort still has a great deal of work to complete, even within a specific
cancer such as FL, to obtain its ultimate goal of a cure. However, we have entered a new era of big
data, high speed automated pipelines, next-generation sequencing, machine learning algorithms,
and have many more tools at our disposal to help us advance towards an inevitable cure. Personal
comprehensive genomic profiles and cancer vaccines play a small role in the grand scheme of
cancer treatment. Genomic profiles provide a snapshot of potential targets to focus on and efforts
to identify novel cancer vulnerabilities within each snapshot and develop drug targets. However,
cancers are complex and constantly evolving to evade death. Because of this, several genomic
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profiles should be taken throughout patient care to actively track the cancer and determine if
treatment adjustments are required. These ever-moving targets require that we attack with a wide
arsenal or multiple treatments at various time points to ensure complete eradication of the tumor
population while maintaining a suitable quality of life for the patient. We currently have all the
tools necessary to make genomic profiles quickly and readily accessible; however, we lack highly
trained individuals to provide and interpret these complex genomic profiles. Genomic profiles are
technically even accessible to patients in rural areas. Their treating physician could simply send
their samples to a large academic of commercial sequencing center elsewhere. These centers
typically process hundreds to thousands of samples a day with the help of automated pipelines that
expedite the analysis and can return results within 2-3 weeks. However, these genomic profiles are
useless without the interpretation and consultation of a highly trained professional and many
variants are identified as “variants of unknown significance” (VUS). This is where trained genomic
professionals, publicly accessible variant interpretation databases, and other resources become
important. Such resources can then help clinicians guide patient treatment and drug discovery.
However, using a patient's genomic profile to understand which treatments to use and avoid
that already exist is not the only thing possible to gain from them. For example, when we are able
to completely characterize the genetic and epigenetic landscape of all cancer, we will also be able
to identify the complete set of driver and passenger mutations of interest. This is specifically
important because we know aging is a major risk factor for cancer development due to the
accumulation of somatic mutations and cellular damage over time (López-Otín et al., 2013;
Moskalev et al., 2013). Therefore, if we are able to identify all major cancer driver mutations that
affect the largest number of people, we could possibly create a general cancer vaccine that could
be administered throughout our lifetime to ensure our immune system actively eliminated these
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targets before expansion. This could theoretically cause a huge decline in the number of cancer
diagnoses. There is still so much more work to be completed and I am very excited to continue my
research.
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Appendix: Clinical data clean up github code
●

●
●
●

###############################################################################
##############
################################## Tidy up and merge clinical data
###############################################################################
##############
library(openxlsx)
library(plyr)
library(dplyr)

●
●
●

# This command desginates my working directory
setwd('~/Box/LymphomaProject/FL_Group2_analysis/ClinicalData/')

●
●

●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●

●
●

###############################################################################
##############
#### Reading in clinical data files
###############################################################################
##############
## Get FL clinical data, 2018 clean data, contains original FL 1 cohorts plus
new patients from FL 2 cohorts
FL_cohorts_1_and_2 <- read.xlsx("~/Box/LymphomaProject/Patient_info/FL clean
june2018.xlsx", colNames = T, startRow = 1)
## Get Alliance clinical data
alliance <- read.xlsx("~/Box/LymphomaProject/Patient_info/A151303 FL clinical
data no PHI.xlsx", colNames=T)
## Get Neoepitope clinical data
neo <- read.xlsx("~/Box/LymphomaProject/Patient_info/neoantigen_noPHI.xlsx",
colNames=T, startRow=2)
## Get Miami clinical data
miami <- read.xlsx("~/Box/LymphomaProject/Patient_info/FL UMiami clinical
data_noPHI.xlsx", colNames=T)
## Get Cleveland Clinic clinical data
clevclin <read.xlsx("~/Box/LymphomaProject/Patient_info/ClevClin_Primary_WU_noPHI.xlsx",
colNames=T, detectDates = F)
## Get Cleveland Clinic clinical data PART 2
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●

●
●
●
●
●

●
●
●
●
●
●
●
●
●
●
●
●
●

clevclin_part2 <read.xlsx("~/Box/LymphomaProject/Patient_info/ClevClin_Primary_WU_noPHI
Part2.xlsx", colNames = T, detectDates = F)
## Removing the last 2 rows as they do not contain any clinical data
clevclin_part2 <- clevclin_part2[-c(16,17), ]
## Get Cleveland Clinic clinical data Previous Treatment
clevclin_prev_treatment <read.xlsx("~/Box/LymphomaProject/Patient_info/ClevClin_Prev Tx_WU _No
PHI.xlsx", colNames=T, detectDates = F)
## Get P2C (Personalis) clinical data
personalis <- read.xlsx("~/Box/LymphomaProject/Patient_info/P2C_NOPHI (all
pts).xlsx", colNames=T, startRow=2)
## Get tNHL clinical data
tNHL <- read.xlsx("~/Box/LymphomaProject/Patient_info/tNHL clinical
data_NOPHI.xlsx", colNames=T, startRow=2)
## Removing the last 2 rows as they do not contain any clinical data
tNHL <- tNHL[-c(47:50), ]
## Marcus: "FL is graded, DLBCL etc are not graded so this isn't a relevant
field"
tNHL$Grade_of_bx_seq <- NA
## Get sample_list_201-05-08.tsv to obtain MGI_sample_names to merge with the
clinical data
MGI_sample_names <read.table("~/Box/LymphomaProject/FL_Group2_analysis/sample_lists/output/sample
_list_2018-11-18.tsv", sep="\t", header=T, stringsAsFactors = F)

●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●

###############################################################################
##############
#### Define universal functions for tidying
###############################################################################
##############
## Clean up headers
sanitize <- function(x) {
n <- colnames(x)
## Remove everything within ()
n <- gsub("(\\.\\(\\S+\\))|(#\\.)","",n,perl=T)
## Replace . or - with _
n <- gsub("\\.|\\-","_",n)
## Replace / with _
n <- gsub("\\/","_",n)
## Replace special characters (,),^,#,>,=,< with nothing
n <- gsub("\\(|\\)|\\^|\\#|>|\\=|<","",n)
## Replace % with perc
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●
●
●
●
●
●

n <- gsub("%","perc",n)
## Replace repeat __ with _
n <- gsub("__","_",n)
colnames(x) <- n
return(x)
}

●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●

## Tidy up additional columns (more human-readable)
human <- function(x) {
## Add NHL type detail (1 = FL, 2 = tNHL)
x$NHL_type <- gsub(2,"t-NHL",x$NHL_type)
x$NHL_type <- gsub(1,"FL",x$NHL_type)
## Add Stage detail (1 = I, 2 = II, 3 = III, 4 = IV)
x$Stage <- gsub(1,"I",x$Stage)
x$Stage <- gsub(2,"II",x$Stage)
x$Stage <- gsub(3,"III",x$Stage)
x$Stage <- gsub(4,"IV",x$Stage)
## Add Grade detail (1; 2; 3 = 3a)
x$Grade_of_bx_seq <- gsub("3$","3A",x$Grade_of_bx_seq,perl=T)
## Add Gender detail (0 = F, 1 = M)
x$Gender <- gsub(0,"F",x$Gender)
x$Gender <- gsub(1,"M",x$Gender)
## Translate Ethnicity (NH = non-Hispanic, H = Hispanic)
if("Ethnicity" %in% colnames(x)){
x$Ethnicity <- gsub("^H","Hispanic", x$Ethnicity,perl=T)
x$Ethnicity <- gsub("^NH","non-Hispanic", x$Ethnicity,perl=T)
}
## Add Race details: (C=Caucasian, AA=African American, A=Asian)
if("Race" %in% colnames(x)){
x$Race <- gsub("C", "Caucasian", x$Race)
x$Race <- gsub("AA", "African American", x$Race)
x$Race <- gsub("^A$", "Asian", x$Race)
}
## Update best response (1 = CR; 2 = PR; 3 = SD; 4 = PD)
resp_cols <- colnames(x)[grepl("esponse", colnames(x))]
for(i in 1:length(resp_cols)) {
cols <- resp_cols[i]
x[,cols] <- gsub(1,"CR",x[,cols])
x[,cols] <- gsub(2,"PR",x[,cols])
x[,cols] <- gsub(3,"SD",x[,cols])
x[,cols] <- gsub(4,"PD",x[,cols])
}
## Add transformation status (0 = N; 1 = Y; 3=Other)
if("Transformation" %in% colnames(x)) {
x$Transformation <- gsub("3","Other",x$Transformation)
}
## Add NHL status (0 = Dx; 1 = R1; 2 = R2; 3 = R3)
if("NHL_status_of_bx_sequenced" %in% colnames(x)) {
x$NHL_status_of_bx_sequenced <- gsub("0","Dx",x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("1","R1",x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("2","R2",x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("3","R3",x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("4","R4",x$NHL_status_of_bx_sequenced)
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x$NHL_status_of_bx_sequenced <- gsub("5", "R5",
x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("6","R6",x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("7","R7",x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("8", "R8",
x$NHL_status_of_bx_sequenced)
x$NHL_status_of_bx_sequenced <- gsub("9", "R9",
x$NHL_status_of_bx_sequenced)
}
## Altering all column names to match
if("T5_treatment" %in% colnames(x)){
colnames(x)[colnames(x) == 'T5_treatment'] <- 'T5_fifth_line_treatment'
}
if("T6_treatment" %in% colnames(x)){
colnames(x)[colnames(x) == 'T6_treatment'] <- 'T6_sixth_line_treatment'
}
if("Best_response_to_T6" %in% colnames(x)){
colnames(x)[colnames(x) == 'Best_response_to_T6'] <- 'Best_Response_to_T6'
}
if("T7_treatment" %in% colnames(x)){
colnames(x)[colnames(x) == 'T7_treatment'] <- 'T7_seventh_line_treatment'
}
if("Best_response_to_T7" %in% colnames(x)){
colnames(x)[colnames(x) == 'Best_response_to_T7'] <- 'Best_Response_to_T7'
}
if("T8_treatment" %in% colnames(x)){
colnames(x)[colnames(x) == 'T8_treatment'] <- 'T8_eighth_line_treatment'
}
if("T8_Treatment" %in% colnames(x)){
colnames(x)[colnames(x) == 'T8_Treatment'] <- 'T8_eighth_line_treatment'
}
if("T8_progression_status" %in% colnames(x)){
colnames(x)[colnames(x) == 'T8_progression_status'] <'T8_Progression_Status'
}
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return(x)
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## Replace all the . with NA
repDot <- function(x) {
x[x == "."] <- NA
return(x)
}

●
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## Generalize discrete variables
generalize <- function(x) {
## Create a binary nodal site column (>4 or not)
x$over4_Nodal_sites <- NA
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## Create a FLIPI group column based on score (0-1 = low, 2 = intermediate,
3-5 = high)
x$FLIPI_group <- x$FLIPI_score
x$FLIPI_group <- gsub("0|1","low",x$FLIPI_group,perl=T)
x$FLIPI_group <- gsub("2","int",x$FLIPI_group,perl=T)
x$FLIPI_group <- gsub("3|4|5","high",x$FLIPI_group,perl=T)
## Replacing "/" in Stage with a "-"
x$Stage <- gsub("/", "-", x$Stage)
## Replacing all unknown values with NA for consistency
x[ x == "U"] <- NA
x[ x == "UKN"] <- NA
x[ x == "unk"] <- NA
x[ x == "Unk"] <- NA
x[ x == "ukn"] <- NA
x[ x == "?"] <- NA
x[ x == "No clinical data available"] <- NA
x[ x == "N/A"] <- NA
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}

return(x)
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###############################################################################
##############
#### Clean up files
###############################################################################
##############
## Tidy up column names
FL_cohorts_1_and_2 <- sanitize(FL_cohorts_1_and_2)
alliance <- sanitize(alliance)
neo <- sanitize(neo)
miami <- sanitize(miami)
clevclin <- sanitize(clevclin)
personalis <- sanitize(personalis)
tNHL <- sanitize(tNHL)
clevclin_part2 <- sanitize(clevclin_part2)
clevclin_prev_treatment <- sanitize(clevclin_prev_treatment)
MGI_sample_names <- sanitize(MGI_sample_names)
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## Tidy up rows
FL_cohorts_1_and_2 <- human(FL_cohorts_1_and_2)
alliance <- human(alliance)
neo <- human(neo)
miami <- human(miami)
clevclin <- human(clevclin)
personalis <- human(personalis)
tNHL <- human(tNHL)
clevclin_part2 <- human(clevclin_part2)
clevclin_prev_treatment <- human(clevclin_prev_treatment)

●
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## Add more general columns
FL_cohorts_1_and_2 <- generalize(FL_cohorts_1_and_2)
neo <- generalize(neo)
miami <- generalize(miami)
clevclin <- generalize(clevclin)
personalis <- generalize(personalis)
tNHL <- generalize(tNHL)
clevclin_part2 <- generalize(clevclin_part2)
clevclin_prev_treatment <- generalize(clevclin_prev_treatment)
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###############################################################################
##############
#### FL_cohorts_1_and_2-specific changes
###############################################################################
##############
# Adding columns to contain adjusted treatment data
FL_cohorts_1_and_2[, c("T9_ninth_line_treatment", "Best_Response_to_T9",
"T9_PFS", "T9_Progression_Status", "adjusted_T1_PFS", "adjusted_T1_PFS_status",
"adjusted_T1_treatment", "adjusted_T1_rituximab_treated",
"adjusted_T1_best_treatment_response", "adjusted_overall_survival_status",
"adjusted_overall_survival", "adjusted_T1_PFS_status_treated",
"adjusted_T1_PFS_treated", "adjusted_overall_survival_status_treated",
"adjusted_overall_survival_treated")] <- NA
FL_cohorts_1_and_2 <- FL_cohorts_1_and_2[, c(1:47, 54:57, 48:53, 58:68)]
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###############################################################################
##############
#### Alliance-specific changes
###############################################################################
##############
## Unavailable data for NHL_status_of_bx_sequenced and Transformation as these
samples are non-WU samples

●
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## Add known but missing fields
alliance$Clinical_T_sequenced <- "T1"
alliance$Sequenced <- "TreatmentNaive"
alliance$Nodal_sites <- NA

●
●
●

## Tidying up a single column name
colnames(alliance) <- gsub("4","over4",colnames(alliance),perl=T)
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## Remove . from throughout table except survival month columns
alliance[,1:18] <- lapply(alliance[,1:18], function(x) repDot(x))
alliance_CleanUp <- function(x) {
## Create a FLIPI group column based on score (0-1 = low, 2 = intermediate,
3-5 = high)
x$FLIPI_group <- x$FLIPI_score
x$FLIPI_group <- gsub("0|1", "low", x$FLIPI_group, perl=T)
x$FLIPI_group <- gsub("2", "int", x$FLIPI_group, perl=T)
x$FLIPI_group <- gsub("3|4|5", "high", x$FLIPI_group, perl=T)
## Replacing all unknown values with NA for consistency
x[ x == "Unk"] <- NA
return(x)
}
alliance <- adply(alliance, 1, alliance_CleanUp)
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###############################################################################
##############
#### Neoepitope cohort-specific changes
###############################################################################
##############
#No changes were made
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###############################################################################
##############
#### Miami-specific changes
###############################################################################
##############
#No changes were made
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###############################################################################
##############
#### ClevClin-specific changes
###############################################################################
##############
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#Creating a complete ClevClin UPN number which was not being converted over
from the excel file
add_id <- function(x){
if(nchar(x$UPN) == 1){x$UPN <- paste0("CCF00", x$UPN)}
if(nchar(x$UPN) == 2){x$UPN <- paste0("CCF0", x$UPN)}
if(nchar(x$UPN) == 3){x$UPN <- paste0("CCF", x$UPN)}
return(x)
}
clevclin <- adply(clevclin, 1, add_id)
# MGI sequence UPNs identified as CCF022, CCF024, and CCF027 which are actually
patients: CCF021, CCF023 and CCF026; Marcus updated the excel file
clevclin$UPN <- gsub("CCF021", "CCF022", clevclin$UPN, perl = TRUE)
clevclin$UPN <- gsub("CCF023", "CCF024", clevclin$UPN, perl = TRUE)
clevclin$UPN <- gsub("CCF026", "CCF027", clevclin$UPN, perl = TRUE)
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###############################################################################
##############
#### ClevClin_Part2-specific changes
###############################################################################
##############
#Note: Patient UPN CCF079 T1_Front_line_treatment is literally "None" because
his OS was 9 days
clevclin_part2$T1_Front_line_treatment <- gsub("None", NA,
clevclin_part2$T1_Front_line_treatment)
#Creating a complete ClevClin_Part2 UPN number which was not being converted
over from the excel file
clevclin_part2 <- adply(clevclin_part2, 1, add_id)
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###############################################################################
##############
#### Cleveland Clinic clinical data Previous Treatment-specific changes
###############################################################################
##############
#Renaming column to ensure consistency
colnames(clevclin_prev_treatment)[1] <- "UPN"
#Removing unnecessary column from dataframe as it was a comment to the reader
clevclin_prev_treatment$T1_in_this_table_is_NOT_frontline_tx_but_the_1st_tx_aft
er_the_sequenced_Bx <- NULL
#Creating new treatment columns to properly organize treatments
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clevclin_prev_treatment[, c("T2_second_line_treatment", "Best_Response_to_T2",
"T2_PFS", "T2_Progression_Status", "T3_third_line_treatment",
"Best_Response_to_T3", "T3_PFS", "T3_Progression_Status",
"T4_fourth_line_treatment", "Best_Response_to_T4", "T4_PFS",
"T4_Progression_Status", "T6_sixth_line_treatment", "Best_Response_to_T6",
"T6_PFS", "T6_Progression_Status", "T7_seventh_line_treatment",
"Best_Response_to_T7", "T7_PFS", "T7_Progression_Status",
"T9_ninth_line_treatment", "Best_Response_to_T9", "T9_PFS",
"T9_Progression_Status")] <- NA
#This function is reassigning what is listed as T1_Front_line_treatment to
their correct treatment times based on the comment left in the file stating:
"T1 in this table is NOT frontline tx but the 1st tx after the sequenced Bx"
correct_treatment_after_bx <- function(x){
if(x$Clinical_T_sequenced == "T2"){
x[ , c("T2_second_line_treatment", "Best_Response_to_T2", "T2_PFS",
"T2_Progression_Status")] <- x[ ,c("T1_Front_line_treatment",
"Best_response_to_T1_Front_Line", "T1_PFS", "T1_Progression_Status")]
}
else if (x$Clinical_T_sequenced == "T3"){
x[ , c("T3_third_line_treatment", "Best_Response_to_T3", "T3_PFS",
"T3_Progression_Status")] <- x[ ,c("T1_Front_line_treatment",
"Best_response_to_T1_Front_Line", "T1_PFS", "T1_Progression_Status")]
}
else if (x$Clinical_T_sequenced == "T4"){
x[ , c("T4_fourth_line_treatment", "Best_Response_to_T4", "T4_PFS",
"T4_Progression_Status")] <- x[ ,c("T1_Front_line_treatment",
"Best_response_to_T1_Front_Line", "T1_PFS", "T1_Progression_Status")]
}
else if (x$Clinical_T_sequenced == "T6"){
x[ , c("T6_sixth_line_treatment", "Best_Response_to_T6", "T6_PFS",
"T6_Progression_Status")] <- x[ ,c("T1_Front_line_treatment",
"Best_response_to_T1_Front_Line", "T1_PFS", "T1_Progression_Status")]
}
else if (x$Clinical_T_sequenced == "T7"){
x[ , c("T7_seventh_line_treatment", "Best_Response_to_T7", "T7_PFS",
"T7_Progression_Status")] <- x[ ,c("T1_Front_line_treatment",
"Best_response_to_T1_Front_Line", "T1_PFS", "T1_Progression_Status")]
}
else if (x$Clinical_T_sequenced == "T9"){
x[ , c("T9_ninth_line_treatment", "Best_Response_to_T9", "T9_PFS",
"T9_Progression_Status")] <- x[ ,c("T1_Front_line_treatment",
"Best_response_to_T1_Front_Line", "T1_PFS", "T1_Progression_Status")]
}
x[ , c(16:19)] <- NA
return(x)
}
clevclin_prev_treatment <- adply(clevclin_prev_treatment, 1,
correct_treatment_after_bx)

●
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###############################################################################
##############
#### Personalis-specific changes
###############################################################################
##############
# We know that none of the personalis samples have a T1 Clinical_T_sequenced
time-point
# Therefore, besides leaving a sample's Clinical_T_sequenced NAed out, we
updated them to Tn which stands for any Clinical_T_sequenced
updating_clinical_T_sequenced <- function(x){
if(is.na(x$Clinical_T_sequenced)){
x$Clinical_T_sequenced <- "Tn"
x$Best_Response_to_T2 <- x$Best_response_to_T1_Front_Line
x$Best_response_to_T1_Front_Line <- NA
x$T2_PFS <- x$T1_PFS
x$T1_PFS <- NA
x$T2_Progression_Status <- x$T1_Progression_Status
x$T1_Progression_Status <- NA
}
return(x)
}
personalis <- adply(personalis,1, updating_clinical_T_sequenced)
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# This simple function helps to identify personalis samples that might have
more than one tumor time point sequenced
multiple_samples <- function(x){
tmp <- data.frame()
if(x$Clinical_T_sequenced != 'Tn' & x$Clinical_T_sequenced !=
x$Ibrutinib_Treatment){
tmp <- x
tmp$Clinical_T_sequenced <- tmp$Ibrutinib_Treatment
}
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return(tmp)
}
add_diff_clinical_t <- adply(personalis, 1, multiple_samples)
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###############################################################################
##############
#### tNHL-specific changes
###############################################################################
##############
## Adding a Transformation column and labeling all samples as transformed
tNHL$Transformation <- 1

●
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###############################################################################
##############
#### MGI_sample_names-specific changes
###############################################################################
##############
#Removing all sample rows that do not have any sequence data produced, such
that sample's overall_coverage is either NA or low coverage
MGI_sample_names <- MGI_sample_names[
which(!is.na(MGI_sample_names$overall_coverage) &
MGI_sample_names$overall_coverage != 'low_coverage'), ]
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###############################################################################
##############
#### Viewing clinical data differences
###############################################################################
##############
colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(neo))]
colnames(neo)[!(colnames(neo)%in%colnames(FL_cohorts_1_and_2))]
colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(miami))
]
colnames(miami)[!(colnames(miami)%in%colnames(FL_cohorts_1_and_2))]
colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(allianc
e))]
colnames(alliance)[!(colnames(alliance)%in%colnames(FL_cohorts_1_and_2))]
colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(clevcli
n))]
colnames(clevclin)[!(colnames(clevclin)%in%colnames(FL_cohorts_1_and_2))]

●

colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(persona
lis))]
colnames(personalis)[!(colnames(personalis)%in%colnames(FL_cohorts_1_and_2))]
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colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(tNHL))]
colnames(tNHL)[!(colnames(tNHL)%in%colnames(FL_cohorts_1_and_2))]

●
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colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(clevcli
n_part2))]
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colnames(clevclin_part2)[!(colnames(clevclin_part2)%in%colnames(FL_cohorts_1_an
d_2))]
colnames(FL_cohorts_1_and_2)[!(colnames(FL_cohorts_1_and_2)%in%colnames(clevcli
n_prev_treatment))]
colnames(clevclin_prev_treatment)[!(colnames(clevclin_prev_treatment)%in%colnam
es(FL_cohorts_1_and_2))]
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###############################################################################
##############
#### Merging of all clinical data to form a single cohort
###############################################################################
##############
## This command iterates through all clinical cohort data frames and merges
them together based on columns
merged_cohort <- Reduce(function(x,y) merge(x,y, all = T),
list(FL_cohorts_1_and_2, alliance, clevclin, miami, neo, personalis, tNHL,
clevclin_part2, clevclin_prev_treatment))
## This command reorders and keeps only the columns found in the
FL_cohorts_1_and_2 data frame
final_cohort <- merged_cohort[ , c(colnames(FL_cohorts_1_and_2), "Prev_Tx",
"Subsequent_treatment", "Treatment_Immediately_After_Biopsy",
"Treatment_Immediately_after_Transformation", "Maintance_Rituximab",
"Ibrutinib_Treatment", "Number_of_cycles_administered",
"Bone_Marrow_Involvement", "Extranodal_sites")]
## This command trims the whitespace before/after all strings
final_cohort <- data.frame(t(apply(final_cohort, 1, trimws)))
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###############################################################################
##############
#### Making universal adjustments to ensure consistency
###############################################################################
##############
## Adjustments concerning Grade_of_bx_seq: Replacing "/" with "-" and Making
all letters Uppercase
adjust_Grade_of_bx_seq <- function(x){
if(!is.na(x$Grade_of_bx_seq)){
if(x$Grade_of_bx_seq != "1-2,focalgrd3a"){
x$Grade_of_bx_seq <- toupper(x$Grade_of_bx_seq)
if(grepl("/", x$Grade_of_bx_seq)){
x$Grade_of_bx_seq <- gsub("/", "-", x$Grade_of_bx_seq)
}
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}
}
return(x)
}
final_cohort <- adply(final_cohort, 1, adjust_Grade_of_bx_seq)
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## Adjustments concerning NHL_type: Anything that is not already coded as “FL”
or “t-NHL” is being coded as “t-NHL”
adjust_NHL_type <- function(x){
if(!is.na(x$NHL_type)){
if(x$NHL_type != "FL"){
if(x$NHL_type != "t-NHL"){
if(x$NHL_type != "composite HL/FL"){
x$NHL_type <- "t-NHL"
if(is.na(x$Comments)){
x$Comments <- x$NHL_type
}
else{
x$Comments <- paste0(x$Comments, ";", x$NHL_type)
}
}
}
}
}
return(x)
}
final_cohort <- adply(final_cohort, 1, adjust_NHL_type)
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## Adjustments concerning Nodal_sites: Considering ClevClin only document up to
4 nodal sites or more, we decided to synchronize all patient clinical data as
such
adjust_Nodal_sites <- function(x){
if(!is.na(x$Nodal_sites)){
if(x$Nodal_sites != "2-3"){
if(x$Nodal_sites != ">4"){
if( as.numeric(as.character(x$Nodal_sites)) > 4){
x$over4_Nodal_sites <- "1"
}
else{
x$over4_Nodal_sites <- "0"
}
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}
else{
x$over4_Nodal_sites <- "1"
}
}
else{
x$over4_Nodal_sites <- "0"
}
}
return(x)
}
final_cohort <-adply(final_cohort, 1, adjust_Nodal_sites)
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## This function fills in the adjust value columns for adjusted treatment
clinical data given the 4 below filters
adjust_T1_treatment <- function(x){
x$tmp <- NA
if(!any(c(is.na(x$Clinical_T_sequenced), is.na(x$T1_Front_line_treatment),
is.na(x$T1_PFS)))){
if(x$NHL_type == "FL"){
if(x$Clinical_T_sequenced == "T1"){
if(x$T1_Front_line_treatment == "Observation" |
x$T1_Front_line_treatment == "OBS"){
if(as.numeric(as.character(x$T1_PFS)) > 12){
x[ , c("adjusted_T1_PFS", "adjusted_T1_PFS_status",
"adjusted_T1_treatment", "adjusted_T1_rituximab_treated",
"adjusted_T1_best_treatment_response", "adjusted_overall_survival_status",
"adjusted_overall_survival", "adjusted_T1_PFS_status_treated",
"adjusted_T1_PFS_treated", "adjusted_overall_survival_status_treated",
"adjusted_overall_survival_treated")] <- x[ ,c("T1_PFS",
"T1_Progression_Status", "T1_Front_line_treatment", "tmp",
"Best_response_to_T1_Front_Line", "Survival_Status_at_Last_Followup",
"Overall_survival", "T1_Progression_Status", "T1_PFS", "T1_Progression_Status",
"Overall_survival")]
}
else{
x[ , c("adjusted_T1_PFS", "adjusted_T1_PFS_status",
"adjusted_T1_treatment", "adjusted_T1_rituximab_treated",
"adjusted_T1_best_treatment_response", "adjusted_overall_survival_status",
"adjusted_overall_survival", "adjusted_T1_PFS_status_treated",
"adjusted_T1_PFS_treated", "adjusted_overall_survival_status_treated",
"adjusted_overall_survival_treated")] <- x[ ,c("T2_PFS",
"T2_Progression_Status", "T2_second_line_treatment", "tmp",
"Best_Response_to_T2", "Survival_Status_at_Last_Followup", "Overall_survival",
"T2_Progression_Status", "T2_PFS", "T2_Progression_Status",
"Overall_survival")]
}
}
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else{
x[ , c("adjusted_T1_PFS", "adjusted_T1_PFS_status",
"adjusted_T1_treatment", "adjusted_T1_rituximab_treated",
"adjusted_T1_best_treatment_response", "adjusted_overall_survival_status",
"adjusted_overall_survival", "adjusted_T1_PFS_status_treated",
"adjusted_T1_PFS_treated", "adjusted_overall_survival_status_treated",
"adjusted_overall_survival_treated")] <- x[ ,c("T1_PFS",
"T1_Progression_Status", "T1_Front_line_treatment", "tmp",
"Best_response_to_T1_Front_Line", "Survival_Status_at_Last_Followup",
"Overall_survival", "T1_Progression_Status", "T1_PFS", "T1_Progression_Status",
"Overall_survival")]
}
}
else if(x$Clinical_T_sequenced == "T2"){
if(x$T1_Front_line_treatment == "Observation" |
x$T1_Front_line_treatment == "OBS"){
x[ , c("adjusted_T1_PFS", "adjusted_T1_PFS_status",
"adjusted_T1_treatment", "adjusted_T1_rituximab_treated",
"adjusted_T1_best_treatment_response", "adjusted_overall_survival_status",
"adjusted_overall_survival", "adjusted_T1_PFS_status_treated",
"adjusted_T1_PFS_treated", "adjusted_overall_survival_status_treated",
"adjusted_overall_survival_treated")] <- x[ ,c("T2_PFS",
"T2_Progression_Status", "T2_second_line_treatment", "tmp",
"Best_Response_to_T2", "Survival_Status_at_Last_Followup", "Overall_survival",
"T2_Progression_Status", "T2_PFS", "T2_Progression_Status",
"Overall_survival")]
}
}
}
}
## Removing the last column as it does not contain any clinical data before
returning
return(x[, -ncol(x)])
}
final_cohort <- adply(final_cohort, 1, adjust_T1_treatment)

●
●
●
●
●
●
●

## Eliminating all white space between characters within the entire dataframe
final_cohort <- as.data.frame(apply(final_cohort,2,function(x)gsub('\\s+',
'',x)))

●
●
●
●
●
●

#tl;dr The following samples are not the same person on paper, but have >90%
shared tested SNPs
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#The following samples have been found to have >90% shared tested SNPs with
another sample that Marcus identified as different patients through their
clinical data
#In an attempt to perserve the largest number of patient's clinical data and
genetic analysis, we decided to NA out all clinical data columns for patients
that match this description and maintain the patient sample where the clinical
data is not in question (because the UPN associated with the clincial data and
genetic data match for this patient)
duplicate_sample_mismatch_clean_up <- function(x){
if(x$UPN %in% c( '500175', '500176', 'FLX060', 'PH1982', 'LYM267', 'PH2028',
'FLX005', '080075031', '080075301', 'TF_UM13', '1029451', '500106', '250678',
'500119', 'CCF105', 'CCF022', 'CCF122', 'CCF024', 'CCF119', 'CCF027', 'CCF117',
'CCF032', 'CCF140', 'CCF045', 'CCF054', 'CCF064', 'CCF084', 'LYM267')){
x[,2:ncol(x)] <- NA
}
return(x)
}
final_cohort <- adply(final_cohort, 1, duplicate_sample_mismatch_clean_up)

●
●
●
●
●
●
●
●
●

●
●
●
●
●
●
●
●
●

●

###############################################################################
#############
#### MERGE SAMPLE INFO AND CLINICAL DATA
# These samples were mislabeled and believed to be total unique patients
# However, the following samples were found to be from already sequenced
patients based on a SNP pairwise correlation analysis but from different tumor
time-points
# H_ML-08-0075-301-1301336_1 is a normal sample merged under UPN PH2020(A/B)
# H_ML-1977-PH1977_pc_fresh_tumor is a sample from a different time-point (T4)
merged under UPN LYM235 time-point (T2)
# H_ML-PH1977-1977_tumor is a sample from a different time-point (T3) merged
under UPN LYM235 time-point (T2)
# H_ML-TFL001-TFL001 is a sample from a different time-point (T1) merged under
UPN 080075174 time-point (T3)
# H_ML-FLX030-FLX030 is a sample from a different time-point (T1) merged under
UPN LYM920 time-point (T2)
# H_ML-TFL005-TFL005 is a sample from a different time-point (T4) merged under
UPN FLX053 time-point (T2)
###############################################################################
##############
# Creating a dataframe excluding specific sequence data samples of interest
that are to be merged with their correct clinical data
MGI_sample_names_incomplete <- MGI_sample_names[ !(MGI_sample_names$Sample %in%
c('H_ML-08-0075-301-1301336_1', 'H_ML-1977-PH1977_pc_fresh_tumor', 'H_MLPH1977-1977_tumor', 'H_ML-TFL001-TFL001', 'H_ML-FLX030-FLX030', 'H_ML-TFL005TFL005')), ]
# Creating a dataframe including specific sequence data samples of interest
that are to be merged with their correct clinical data
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multiple_patient_sample_corrections <- MGI_sample_names[MGI_sample_names$Sample
%in% c('H_ML-08-0075-301-1301336_1', 'H_ML-1977-PH1977_pc_fresh_tumor', 'H_MLPH1977-1977_tumor', 'H_ML-TFL001-TFL001', 'H_ML-FLX030-FLX030', 'H_ML-TFL005TFL005'), ]
# Making a function that changes the UPNs
alias_UPNs <- function(x){
x <- switch(EXPR = as.character(x), '080075301'='PH2020(A/B)',
'LYM235'='PH1977', '080075174'='TFL001', 'LYM920'='FLX030', 'FLX053'='TFL005',
'080075260'='FLX058_2')
}
switch_back <- function(x){
x <- switch(EXPR = as.character(x), 'PH2020(A/B)'='PH2020(A/B)',
'PH1977'='LYM235', 'TFL001'='080075174', 'FLX030'='LYM920', 'TFL005'='FLX053')
}
# This function merges the correct clinical data with its appropriate sequence
data
adjust_UPN <- function(x){
tmp <- x
tmp$UPN_clinical <- sapply(tmp$UPN_clinical, alias_UPNs)
tmp <- merge(tmp, final_cohort, by.x = 'UPN_clinical', by.y = 'UPN')
tmp$UPN_clinical <- sapply(tmp$UPN_clinical, switch_back)
return(tmp)
}
multiple_patient_sample_corrections <adply(multiple_patient_sample_corrections, 1, adjust_UPN)
# Merging the sequence data with their appropriate clinical data
final_cohort_seq_clinical_data <- merge(MGI_sample_names_incomplete,
final_cohort, by.x = "UPN_clinical", by.y = "UPN", all.x = TRUE)
# Concatenating sequence and clinical data dataframes to include all the
patinets
final_cohort_seq_clinical_data <- rbind(final_cohort_seq_clinical_data,
multiple_patient_sample_corrections)

●
●
●
●
●
●

●
●

###############################################################################
##############
#### ALTER CLINICAL T SEQUENCED DATA
# A subset of samples below require that their clinical tumor sequenced be
updated based on the following criteria laid out below
###############################################################################
##############
increment_clinical_t_sequenced <- function(x){
x <- switch(EXPR = as.character(x), 'T1'='T2', 'T2'='T3', 'T3'='T4',
'T4'='T5', 'T5'='T6', 'T6'='T7', 'T7'='T8', 'T8'='T9', 'T9'='T10', 'Tn'='Tn',
'NA'='NA')
return(x)
}

●
●

Tn_clinical_t_sequenced <- function(x){

●
●
●
●
●
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x <- switch(EXPR = as.character(x), 'T1'='Tn', 'T2'='Tn', 'T3'='Tn',
'T4'='Tn', 'T5'='Tn', 'T6'='Tn', 'T7'='Tn', 'T8'='Tn', 'T9'='Tn', 'Tn'='Tn',
'NA'='NA')
}
adjust_clinical_t_sequenced <- function(x){
tmp <- x
if( (x$UPN_clinical %in% c('PH1967', 'PH1969', 'PH1972', 'PH2040', 'LYM235')
& grepl('pc', x$Sample)) ){
tmp$Clinical_T_sequenced <- x$Ibrutinib_Treatment
}
else if( (x$UPN_clinical %in% c('PH1966', 'PH2060') & grepl('relapse',
x$Sample)) ){
tmp$Clinical_T_sequenced <- sapply(x$Clinical_T_sequenced,
increment_clinical_t_sequenced)
}
else if( (x$UPN_clinical %in% c('080075120') & grepl('relapse',
x$common_name)) ){
tmp$Clinical_T_sequenced <- sapply(x$Clinical_T_sequenced,
increment_clinical_t_sequenced)
}
else if( (x$UPN_clinical %in% c('080075260') & grepl('relapse',
x$common_name)) ){
tmp$Clinical_T_sequenced <- 'T3'
}
else if( x$Sample == 'H_ML-DNA_1990_relapse-PH1990_relapse_pc_fresh_tumor'){
tmp$Clinical_T_sequenced <- sapply(x$Clinical_T_sequenced,
increment_clinical_t_sequenced)
tmp$NHL_type <- 't-NHL'
}
return(tmp)
}
final_cohort_seq_clinical_data <- adply(final_cohort_seq_clinical_data, 1,
adjust_clinical_t_sequenced)

●
●
●
●
●
●
●
●
●
●
●
●
●
●
●

###############################################################################
##############
#### NAing out all clinical data was too aggressive
# A subset of samples below require that their NHL_type be reinstated as FL
given the following reasoning
# If UPN starts with “PH” and NHL_type is “NA” make it “FL”
# If UPN starts with “CCF” and NHL_type is “NA” make it “FL”
# If sample mix up and NHL_type are both “FL” make it “FL”
###############################################################################
##############
recover_NHL_type <- function(x){
if(is.na(x$NHL_type)){
x$NHL_type <- "FL"
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}
return(x)
}
final_cohort_seq_clinical_data <- adply(final_cohort_seq_clinical_data, 1,
recover_NHL_type)

●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●

###############################################################################
##############
#### Isolating patients with both clinical and sequence data.
#### Any sequence data without any clinical data at all are removed from the
final clinical data file
###############################################################################
##############
FL_Group2_clinical_data_cleaned <- final_cohort_seq_clinical_data[, c(1,
35:110)]
colnames(FL_Group2_clinical_data_cleaned)[1] <- 'UPN'
FL_Group2_clinical_data_cleaned <FL_Group2_clinical_data_cleaned[!duplicated(FL_Group2_clinical_data_cleaned), ]
remove_clinical_na <- function(x){
if( all(is.na(x[, 2:ncol(x)])) == FALSE){
return(x)
}
}
FL_Group2_clinical_data_cleaned <- adply(FL_Group2_clinical_data_cleaned, 1,
remove_clinical_na)

●
●
●
●
●
●
●
●
●
●

###############################################################################
##############
#### Outputting data files
###############################################################################
##############
## Outputing the final cohort clinical data merged with the correct sequence
data
write.table(final_cohort_seq_clinical_data,
file="master_clinical_data_file_merged_sequenced_data_file.tsv",
sep="\t",row.names=F,quote=F)

●
●
●
●
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#This table contains all unique tumor samples from the entire cohort.
Therefore, a patient with 2 different tumor samples will be represented twice.
#There are a total of 515/550 samples sequenced. (Normal or tumor samples from
various patients)
#There are a total of 360 unique patients. (There were originally believed to
be more patients, but a SNP correlation analysis determined that some patients
had been sequenced more than once and represented as another patient)
write.table(FL_Group2_clinical_data_cleaned,
file="master_clinical_data_file.tsv", sep="\t",row.names=F,quote=F)

●
●
●
●
●
●
●
●
●

●

#This clinical data file is incomplete as it contains:
#1) Duplicated patients
#2) Patients that are duplicated have multiple UPNs as they were believed to be
totally different patients,
#3) Patients that were found to be genetically correlated with another sample
but could not be determined which clinical data to use (These samples were
completely NAed out clinically)
#write.table(final_cohort, file="master_clinical_data_file.tsv",
sep="\t",row.names=F,quote=F)
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